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Life is what happens while you are busy making other plans. 
 
(Leben ist das, was passiert, während du dabei bist, andere Pläne zu schmieden.) 
 
John Lennon, 1940-1980 (British musician) 
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1. Introduction 
 
1.1 Structure and barrier function of human skin  
The skin is one of the largest barriers of the human body and is divided into three layers: the 
subcutis, dermis and epidermis with individual functions for each layer. The main function of the 
subcutaneous tissue is to guarantee the skin flexibility to subjacent muscle layers and fascia. The 
dermis is located above the subcutaneous layer and has different functions. Sweat glands e.g. are 
located in this part of skin. These glands are responsible for cooling the body by producing sweat 
and transport it through sweat ducts to the pore of the skin surface. Another important function of 
the dermis is to provide nutrients for the epidermis. This is required because there are no blood 
vessels in the epidermis. Fibroblasts are the predominant cell type in the dermis besides dermal 
dendritic cells (dDCs) and macrophages, circulating immune cells (Ochoa et al., 2008).  
The much thinner epidermis is divided into the stratum basale, stratum spinosum, stratum 
granulosum and stratum corneum. The stratum basale lies on top of the lamina basale, which 
separates the epidermis and dermis and organizes the diffusion of nutrients and growth factors 
between the two skin layers (Steusloff et al., 2000) (Figure 1.1).  
Some keratinocytes and hair follicles of the stratum basale are known as epidermal stem cells and 
remain attached to the basement membrane and produce daughter cells by asymmetric mitosis 
(Lechler and Fuchs, 2005). Basal keratinocytes are anchored by hemidesmosomes to the basal 
membrane, whereas in the stratum spinosum, keratinocytes are interconnected by desmosomes 
(Ghadially et al., 1996). Keratinocytes in the stratum granulosum further cornificate: their 
morphological structure change, they lose their rounded shape and start to express terminal 
differentiation markers, such as involucrin.  
In the stratum corneum, keratinocytes release specialized lysomal enzymes to degenerate cell 
organelles and their nucleus. In this layer, the keratinocytes are very tightly linked and form the 
cutaneous barrier (Candi et al., 2005). In healthy skin, the epidermal maturation takes about two to 
four weeks and includes cell proliferation, migration and terminal differentiation of epidermal 
keratinocytes (Fuchs and Byrne, 1994). 
The differentiated layers of the epidermis protects the proliferating layer from induced cell stress, 
such as physical, mechanical as well as ultraviolet- (UV-) light (cornified envelope) (Schröder and 
Harder, 2006).  
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On the way to cornification, different 
keratinocyte proteins, e.g. involukrin 
or loricrin, become biochemically 
cross-linked by the transglutaminase I 
(TGase I). This process ensures the 
mechanical stability of the epidermis 
(Denecker et al., 2008; Eckhart et al., 
2000). Of course, the most prominent 
cells of the epidermis are 
keratinocytes, but also melanocytes 
and Langerhans cells (LC) can be 
found. However, melanocytes are 
important to protect the skin from 
UV-induced photo damage by 
transferring melanin in melanosomes 
into keratinocytes through dendritic 
projunctions (Seiberg, 2001). These 
cells are located between 
keratinocytes in the basal layer of the 
epidermis. Langerhans cells are 
specialized dendritic cells and present in all layers of the epidermis. In skin infection, LCs get 
activated and can induce the adaptive immune system (Kaplan, 2010).  
The classification of ultraviolet light (UVR) depends on the energy levels, thus, of the wavelength. 
UVC has a low wavelength and a high energy level, whereas UVB has a higher wavelength but a 
lower energy level. Emitted by the sun, approximately 5% of the electromagnetic radiation reaches 
at the earth’s surface (Soehnge et al., 1997), and of this 90 - 95% is ultraviolet light A (UVA) and 5 - 
10% is UVB radiation. UVB and UVA penetrate into the dermis and percolate the transitional zone 
(tz) and the stratum basale (sb), the cell layers where the cell cycle is active (Figure 1.2) (Timares et 
al., 2008). UVC has a shorter wavelength and is absorbed by the atmospheric ozone layer and does 
not reach the earth’s surface (Diffey, 2002). 
 
Figure 1.1: Schematics of epidermal maturation. Keratinocytes 
in the proliferating layer, the stratum basale, are connected to 
the lamia basale via hemidesmosomes. In this layer, 
keratinocytes are constantly renewed by proliferation. In the 
above layer, the stratum spinosum, keratinocytes exit from the 
cell cycle, and start to differentiate. Their cell-cell contact is 
warranted by desmosomes. In higher layers of the stratum 
spinosum the keratinocyte cytoskeleton is reinforced. In the 
stratum granulosum the keratinocytes change their conformation 
and express late differentiation markers e.g. filaggrin or loricrin. 
In the stratum corneum the nucleus of keratinocytes is degraded 
and the cells form the cornifed envelop by cornification. In the 
last stratum corneum layer dead keratinocytes are shedded. 
Keratinocytes maturation is a continuous process and needs 
about 2-4 weeks is healthy skin (Denecker et al., 2008).  
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UVR induces DNA damage in different 
dimensions. The best known are cyclobutane 
pyrimidine dimers which develop after UVB 
irradiation. UVA is responsible for about 10% 
of the DNA damage by inducing double strand 
breaks (Greinert et al., 2012). It is also known 
that high doses of UV irradiation lead to 
strong inflammation of the skin, known as 
sunburn. However, even a suberythematous 
dose of UVB is able to induce cytokine 
expression. It has been shown that UVB works 
as a danger signal for human epidermal 
keratinocytes. It activates certain cytosolic 
receptor complexes, called ‘inflammasomes’ 
that cleave the pro-inflammatory cytokine interleukin-1β (IL-1β) into its active form and in turn 
induce inflammation (Martinon et al., 2002). As protection against biological stress, the skin pH 
under 5 is considered normal, which allows colonization of the skin surface with the so called 
‘commensal microflora’ (Lambers et al., 2006).Under these conditions, just specialized harmless 
microorganisms survive, and leave not enough habitat for potential harmful pathogens. Otherwise, 
harmful pathogens activate the immune system of the skin.  
 
1.2 Innate and adaptive immunity in the skin 
The immune system is a complex defense system to protect the host from infiltrating pathogens and 
can be classified into the innate or non-specific, and the adaptive or specific immunity. Different cell 
types and mechanisms are responsible for recognizing infiltrating pathogenic microorganisms as fast 
as possible to avoid their expansion. The classical immune cells of the blood differentiate from 
hematopoietic stem cells, which develop in the bone marrow. Hematopoietic stem cells split into 
lymphoid and myeloid progenitor cells. Matured cells of these progenitors can also be divided into 
adaptive and innate immunity. 
The innate immunity is the first line of defense and discriminates ‘self’ non-danger and ‘non-self’ 
danger signals to protect the host from incoming pathogens. Already in 1994, the group around 
Matzinger published the ‘danger hypothesis’, which says, that the innate immune system recognizes 
danger signals and tolerates non-dangerous situations. As a consequence of danger, antimicrobial or 
tissue repair functions get activated to prevent massive damage in harmless situations, like the 
 
Figure 1.2:  Schematic diagram of the UV-light 
spectrum and how deep it penetrates into the human 
skin. stratum corneun (sc) stratum granulosum (sg) 
stratum spinosum (ss) transitional zone (tz) and stratum 
basale (sb) (modified: (Timares et al., 2008)). 
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commensal gut flora (Matzinger, 1994). Equipped with a large range of germline-encoded pattern-
recognition receptors (PRRs) the innate immune system detects highly conserved and invariant 
microbial motifs. Not only classical immune cells, like macrophages, DCs or neutrophils express 
these receptors, they are also expressed by non-classical cells like epidermal keratinocytes.  
Monocytes mature from myeloid progenitor cells and circulate constantly with the blood stream 
through the body and migrate into the tissue upon tissue damage or cell stress where they 
differentiate into macrophages. Macrophages take up small particles and pathogens by 
phagocytosis. Activated macrophages can induce a local immune reaction by secreting cytokines, 
like interleukin-1 (IL-1) or tumor-necrosis-factor-α (TNFα), as well as chemokines. Further, 
macrophages can activate other immune cells to induce an adaptive immune answer. Another cell 
type, capable of phagocytosis, are neutrophil granulocytes. They circulate in the blood but have a 
shorter turnover compared to macrophages. Frequently, neutrophils are recruited very fast to the 
center of inflammation and amplify the immune reaction. Also dendritic cells (DCs) and Langerhans 
cells, specialized dendritic cells located in the epidermis, build an important link between innate and 
adaptive immunity. After activation of DCs by pathogens or particles, their morphological structure 
change chemokine receptors are increasingly expressed, and further DCs migrate into the draining 
lymph nodes. In the lymph node, DCs act as professional antigen presenting cells (APCs) by 
presenting antigens on their surface, to activate naïve B and T cells (Janeway and Medzhitov, 2002). 
One exception are natural killer cells (NK), they belong to the innate immune system but develop 
from common lymphoid progenitor cells (Wang and Wagers, 2011).  
B and T cells belong to the adaptive immunity and develop in the bone marrow, where B cells 
mature. However, T cells mature in the thymus. Two main T cell subtypes are known: the CD4+ and 
the cytotoxic CD8+ T cells. The differentiation into naïve CD4+ or CD8+ T cells occurs in the thymus, 
whereas differentiation of naïve CD4+ T cells is caused by the surrounding cytokine-milieu. Th1 cells 
are induced through the cytokines IL-12 or interferon-γ (IFNγ) that are produced by innate immune 
and NK cells. T cells that differentiate to Th1 subpopulation mainly express IFNγ and are induced to 
operate against extracellular microorganisms, like viruses. In contrast, IL-2, IL-4 and IL-15 induce Th2 
cells, which express IL-4, IL-5 and IL-13 and support the immune answer against extracellular 
pathogens, like worms and parasites. Another surrounding cytokine-milieu of IL-6, IL-21 and IL-23 
induce the Th17 cell subpopulation that expresses mainly IL-17A and IL-22. Both cytokines affect the 
immune response against extracellular bacteria and fungi (Chen et al., 2007; Zhou et al., 2009).  
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1.2.1 The inflammasome  
A large family of pattern recognition receptors (PRRs) is called nucleotide-binding oligomerization 
domain (NOD)-like receptor (NLR) and is mostly found on cells of the immune system including many 
epithelia cells. NLRs are soluble and located in the cytosol (Shaw et al., 2008). All members of the 
NLR-family are characterized by the presence of a central nucleotide-binding and oligomerization 
(NACHT) domain that allows the activation by adenosine triphosphate (ATP)-dependent 
oligomerization. Usually, the highly conserved leucin-rich-regions (LRRs) are located at the C-
terminus, whereas the caspase recruitment (CARD) or pyrin (PYD) domains are flanking at the N-
terminus. The LRRs of NLRs act as ligand sensing domains. With their LRRs and via CARD-CARD 
interaction the NF-κB transcription factor gets activated (Schroder and Tschopp, 2010). The NLR-
family is divided into two subgroups: the nucleotide-binding oligomerization domain-containing 
protein (NOD) and the NACHT, LRR and PYD domains-containing protein (NALP, also known as NLRP 
or CARD7) (Ting et al., 2008). NLR-family members sense cytoplasmatic pathogen associated 
molecular patterns (PAMPs), like muramyl dipeptides, and danger associated molecular patterns 
(DAMPs), like an increased ATP concentration in the cell. Activation of NLRs, such as NALP1 or 
NALP3, assemble large multi-molecular complexes which are named ‘inflammasomes’ and activate 
pro-inflammatory caspases (Martinon et al., 2002; Martinon and Tschopp, 2007). Caspases are 
cystein proteases which can initiate pro-inflammatory and pro-apoptotic signaling pathways, leading 
to inflammation or cell death. Caspase-1, caspase-4 and caspase-5 are pro-inflammatory caspases, 
whereas caspase-3, caspase-7 and caspase-9 are apoptotic caspases.  
An exception is caspase-12, which is not categorized yet because the caspase-12 gene is mutated 
and the protein is non-functional in human (Martinon et al., 2002; Xue et al., 2006). Caspase-14 
plays a unique role. In the skin, this cystein protease is only expressed in the cornified epithelium. 
Activation of caspase-14 correlates with the cornification, indicating a role in differentiation and 
proliferation. Profilaggrin is a direct substrate of caspase-14 (Denecker et al., 2007) whereas pro-IL-
1β and pro-IL-18 cannot be cleaved by caspase-14 (Denecker et al., 2008; Mikolajczyk et al., 2004). 
The first identified member of the NOD like receptor (NLR) family that is able to form a large 
inflammasome protein complex is the NACHT, LRR and PYD domains-containing protein 1 (NALP1). 
The NALP1 domain organization is unique compared to other NLR-family members. Like all family 
members, on the N-terminus a PYD domain is located followed by the LRR. A function to find domain 
(FIIND) and CARD motif is found at the C-terminus that associates with the adaptor molecule 
apoptosis-associated speck-like protein (ASC) by a PYD-PYD homotopic interaction (Figure 1.3) 
(Martinon et al., 2001). 
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The term ‘inflammasome’ developed in 
2002, where it has been shown the first 
time that a caspase-1 activation high-
molecular protein complex consists of 
caspase-1, caspase-5, ASC and NALP1 
protein (Martinon et al., 2002). NALP1 is 
expressed in different tissues and cell 
types: in high levels in brain, little in 
epithelial tissues, testis, alveolar 
macrophages, peripheral blood 
mononuclear cells (PBMCs) (Kummer et 
al., 2007). Two well-known activators of 
the NALP1 inflammasome are anthrax 
lethal factor (LF) expressed by the Bacillus 
anthracis and muramyl dipeptide (MDP), 
a membrane component of bacteria (Fink 
et al., 2008; Hsu et al., 2008). Another 
NLR member, NOD2, acts as an 
intracellular MDP sensor, and the N-
terminal CARD domains activate the 
transcription factor NF-κB, beside others (Girardin et al., 2003). A direct interaction of NOD2 with 
NALP1 but not with NALP3 das been described, thus NOD2 is an important mediator for the NALP1 
inflammasome activation (Hsu et al., 2008). Compared to other NALPs, NALP1 is able to interact with 
both pro-inflammatory caspase-1 and caspase-5 (Martinon et al., 2002).  
A large range of sterile mediators like ATP, cholesterol crystals as well as bacterial pathogens, such 
as S. aureus, E. coli, Shigella flexneri and viral pathogens like adenovirus, influenze A and vaccina 
viruses are known to activate the NACHT, LRR and PYD domains-containing protein 3 (NALP3) 
inflammasome (Broz et al., 2010; Craven et al., 2009; Duewell et al., 2010; Rock et al., 2010; Warren 
et al., 2008). Also environmental activators, like UV irradiation or alum are described as potential 
activators (Feldmeyer et al., 2007; Kool et al., 2008; Li et al., 2008; Watanabe et al., 2007).  
Not only members of the NLR-family assemble inflammasome complexes, also others like the absent 
in melanoma 2 (AIM2), that belongs to the pyrin and HIN domain-containing protein (PYHIN) family, 
build an inflammasome. Four scientific working groups showed independently that the AIM2 
inflammasome is a sensor for double-stranded (ds) DNA in an ASC dependent manner 
(Burckstummer et al., 2009; Fernandes-Alnemri et al., 2009; Hornung et al., 2009; Roberts et al., 
 
Figure 1.3: Structure and composition of the NALP1, NALP3 
and AIM2 inflammasomes. NALP1 and NALP3 belong to the 
NOD like receptor (NLR)-protein family and have leucin rich 
regions (LRR) to recognize the PAMP or DAMP. Instead of this 
region AIM2 has a HIN200 domain to where free cytosolic 
DNA bind and activate the inflammasome. The 
oligomerization and interaction domain of NALP1 and NALP3 
are comparable, both protein complexes share the protein 
CARDINAL and the adaptor protein ASC. Not CARDINAL but 
ASC could be found in the AIM2 inflammasome. All the 
inflammasomes shown here have a card binding domain with 
the caspases in common. Some inflammasomes interact with 
one (AIM2) or two (NALP3) caspase-1 proteins, however 
NALP1 bind caspase-1 and caspase-5 via the CARD binding 
protein (modified: (Sidiropoulos et al., 2008; Stutz et al., 
2009)). 
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2009). The activated AIM2 molecule recruits the adaptor ASC, thus pro-caspase-1 gets activated. The 
HIN200-domain directly binds dsDNA, indicating to be a direct cytosolic dsDNA receptor (Figure 1.3) 
(Hornung et al., 2009). Because of the capability to recognize prokaryotic and eukaryotic DNA the 
connection to auto-inflammatory immune diseases is close (Hornung et al., 2009). 
Beside the protective role of inflammasomes to recognize different DAMPs and PAMPs, which 
induce a fast immune response, some inflammatory diseases are linked to a constitutive 
inflammasome activation (Schroder and Tschopp, 2010). Dysfunction of inflammasome complexes 
can have pathogenetic consequence. IL-1β is the most prominent member and is a very potent pro-
inflammatory cytokine, that is responsible for many different chronic and acute inflammatory and 
auto-inflammatory diseases like cryopyrin-associated periodic syndrome (CAPS), familial 
mediterranean fever (FMF), rheumatoid arthritis and many more (Dinarello, 2011). A mutation in the 
NACHT domain of NALP3 leads to constitutively high active IL-1β levels. The mutation has been 
described in CAPS (Aganna et al., 2002; Agostini et al., 2004). Different auto-inflammatory 
diseases, like type 2 diabetes (Larsen et al., 2009), are treated by blocking IL-1β with its natural 
occurring antagonist IL-1Ra, (anakinra, Kineret™) (Dinarello, 2011). However, the expression, 
 
Figure 1.4: Schematics of priming and activation of the NALP3 inflammasome. Two signals are needed to 
activate the inflammasome. First the expression of pro-IL-1β and pro-caspases need to be induced. LPS 
amongst others PAMPs activates the NF-κB signaling cascade by binding to TLR that induce the expression of 
pro-IL-1β. The second signal is needed to activate the NALP3. Different stimuli are known, like toxins or gout 
crystals to activate the NALP3 by oligomerization. The oligomirized NALP3 inflammasome recruits ASC via a 
PYD-PYD interaction pro-caspase-1 binds to the complex. With a proteolytic cleavage pro-caspase-1 gets 
activated thus the active caspase-1 cleaves pro-IL-1β into the biologic active IL-1β. Mature IL-1β is released 
into the extracellular space (Sidiropoulos et al., 2008). 
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regulation and function of inflammasomes in chronic inflammatory skin diseases like psoriasis are 
poorly described.  
To activate inflammasomes priming and activation are needed. Toll-like receptors (TLRs), another 
highly conserved membrane bound receptor family, recognize PAMPs, such as LPS. Upon activation, 
NF-κB translocates into the nucleus and results in an increased expression of pro-IL-1β and caspases. 
The second stimuli are intracellular located DAMPs, like high amounts of ATP or PAMPs, like 
bacterial toxins that cause an oligomerization of the inflammasomes. The oligomerized 
inflammasome complex recruits ASC, which in turn binds through a PYD-PYD interaction with the 
inactive pro-caspase-1. Activated inflammatory caspases in turn cleave pro-IL-1β and pro-IL-18 into 
their biologic active forms. The mature IL-1β is secreted into the extracellular space and further 
induces signal transduction via its specific IL-1 receptor (Figure 1.4) (Sidiropoulos et al., 2008).  
The IL-1 receptor typ I (IL-1RI) is membrane stable and IL-1α and IL-1β bind in the first step to the 
ligand binding domain (IL-1RI) followed by the recruitment of the co-receptor chain IL-1R accessory 
protein (IL-1RAcP). Intracellular signaling starts with the recruitment of MyD88 to the TIR domain. 
The structure of this part of the receptor is shared with the TLRs and results in a translocalization of 
NF-κB into the nucleus and induction of pro-inflammatory cytokines (Weber et al., 2010).  
The IL-1 receptor antagonist (IL-1Ra) binds to IL-1RI and blocks a complex with IL-1RAcP, thus no 
signal transduction is induced (Dinarello, 2011). Pro-IL-1β, a precursor, needs to be activated by a 
pro-inflammatory caspase (see above). After cleavage, different mechanisms are described for the 
release of mature IL-1β like by secretory lysosomes or the caspase-1 dependent pyroptosis (Andrei 
et al., 2004; Bergsbaken et al., 2009). Also a caspase-1 independent processing of IL-1β has been 
described, for example, IL-1β irritant-induced inflammation in muscle tissue (Fantuzzi et al., 1997). 
Proteases of infiltrating neutrophils, like proteinase-3 are known to cleave pro-IL-1β into its active 
form caspase-1 independently (Fantuzzi et al., 1997; Joosten et al., 2009). Some matrix-
metalloproteinases are also responsible for a caspase-1 independent IL-1β cleavage, mainly 
stromelysin-1 (MMP3) gelatinases a (MMP2) and b (MMP9) (Schonbeck et al., 1998).  
Another pattern recognition receptor is the receptor for advanced glycation end products (RAGE) 
that belongs to the immunoglobulin superfamily of surface receptors (Neeper et al., 1992; Schmidt 
et al., 1992). In healthy tissues and cells the expression of RAGE is low, but an increased expression 
can be found in other inflammatory diseases like diabetes, atherosclerosis and cancer (Bierhaus and 
Nawroth, 2009; Gebhardt et al., 2008; Hofmann et al., 1999; Park et al., 1998). On a variety of cell 
types RAGE is expressed pre- and postnatal, the expression decreases with aging and is found in 
alveolar cells and some other cell types (Bierhaus and Nawroth, 2009; Schmidt et al., 2001). This 
transmembrane receptor has an extracellular V-, C1- and C2-domain, a short membrane spanning 
domain and a cytoplasmatic and transduction domain. Different ligands have been described, such 
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as advanced glycation end-products (AGEs), high mobility group box-1 (HMGB1) and so called groups 
of the antimicrobial peptides like many S100-proteins (Fages et al., 2000; Hofmann et al., 1999; 
Huttunen et al., 1999; Xue et al., 2011). Activation of RAGE can result in inflammation and tumor 
progression, increased expression of the receptor itself, cell proliferation, differentiation and 
promotes autophagy, depending on the associated ligand and the cell type (Kang et al., 2010; Sorci 
et al., 2013). The functional link between inflammasome activity and the activation of RAGE is poorly 
investigated. 
1.2.2 Antimicrobial peptides  
Small peptides of different protein families with the capacity to defend microorganisms belong to 
the group of ‘antimicrobial peptides’ (AMPs). Expression of AMPs has been described in plants and 
invertebrates and which show a high conservation throughout evolution of these small peptides that 
belong to the innate immunity (Boman, 2003). Many AMPs exert different mechanisms to regulate 
the immune system e.g. recruitment and activation of antigen-presenting cells, thus they act as 
chemoattractants (Oppenheim and Yang, 2005). In humans, AMPs are constitutively expressed e.g. 
in neutrophils, eosinophils and platelets and additionally in non-immune cells, such as epidermal 
keratinocytes, further AMPs are inducible upon mechanical or microbial injury (Harder and Schroder, 
2005).  
Exemplary, the human β-defensins (hβD) are small, 4-5 kDa cationic peptides, which show a high 
activity against a large spectrum of microorganisms like bacterial, viral and fungi (Schibli et al., 2002). 
The best described member of this family is hβD-1. First discovered in blood and urine, hβD-1 was 
also detected in breast milk and the respiratory tract (Singh et al., 1998) as well as in gland epithelial 
(Jia et al., 2001; Valore et al., 1998) and epithelial tissue (Fulton et al., 1997). HβD-1 shows an 
antimicrobial activity against microorganisms like Escherischia coli (E. coli) or Pseudomonas 
aeroginosa (P. aeroginosa) (Singh et al., 1998; Zucht et al., 1998). In addition to the AMP function, a 
chemotactic activity of hβD-1 on immature DCs and memory T cells can be observed (Yang et al., 
1999). Another class of AMPs are the cathelicidins. Humans just encode for one gene that expresses 
the hCAP18, where cathelin is located at the N-terminus and the antimicrobial domain at the C-
terminus (Agerberth et al., 1995; Gudmundsson et al., 1996). Mainly expressed in neutrophils but 
also deteced in lymphocytes and epithelia tissue (e.g. skin, intestine) hCAP18 is cleaved by 
proteinase-3 and the antimicrobial C-terminal LL-37 is functional active (Nizet and Gallo, 2003; 
Sorensen et al., 2001; Zanetti, 2005). LL-37 affects Gram-positive as well as Gram-negative bacteria 
(Turner et al., 1998), and various numbers of viruses like herpes simplex virus (HSV), adenovirus and 
vaccinia virus has been described (Gordon et al., 2005; Howell et al., 2006; Howell et al., 2004). LL-37 
is also an immune modulator and affects e.g. cell proliferation, wound healing, angiogenesis and 
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influences the release of pro-inflammatory cytokines as well as histamine (Bals and Wilson, 2003; 
Bowdish et al., 2005).  
The name of the S100 family, another large AMP-family, derived from their biochemical 
characteristic: to be 100% soluble in ammonium sulfate at a neutral pH (Moore, 1965). Produced as 
inactive monomers, S100-proteins di- or polymerize spontaneously. After binding of calcium, in 
some cases also zinc or copper, the di- or polymerized proteins are able to activate intracellular 
target proteins (Wolf et al., 2010b; Zimmer et al., 2003). The 9-13 kDa big S100-proteins are 
characterized by two calcium-binding EF-hand motifs mediate different functions in cells and tissues, 
e.g. cell proliferation, differentiation and cytoskeletal membrane interactions, additionally they also 
act as chemoattractants for leukocytes (Eckert et al., 2004; Heizmann et al., 2002). S100-gene 
duplications during evolution created many S100 variants that are different in function and diversity 
(Kulski et al., 2003; Wolf et al., 2010a). Beside psoriasin (S100A7) the calcium and zinc-binding 
heterodimer of S100A8/S100A9, so called ‘calprotectin’, also act as an AMP against the fungi 
Candida albicans (C. albicans) (Clohessy and Golden, 1995; Sohnle et al., 2000). The main producers 
of calprotectin are neutrophils, monocytes, macrophages and epidermal keratinocytes (Nacken et 
al., 2003). 
More AMPs are known and the most of them share a characteristic, cationic surface charge, which 
allows them to bind to microorganisms. For this reason, AMPs can also make pores into the cell 
membrane of pathogens and cause their depletion (Park and Hahm, 2005). 
1.2.3 Psoriasin (S100A7) and koebnerisin (S100A15) – highly homologous but distinct 
Psoriasin (S100A7) was first discovered up-regulated in lesional skin of patients with plaque 
psoriasis, after which the protein was named (Madsen et al., 1991). In 2003, koebnerisin (S100A15) 
has been described over-expressed in koebnerized skin (Wolf et al., 2003). The feature of non-
lesional psoriatic skin is that upon various environmental triggers, such as inflammatory or 
mechanical stimuli, inflammatory lesions develop, and has beed described as koebner phenonenom. 
Mainly produced by keratinocytes, psoriasin (S100A7), is also located in areas with high bacterial 
colonization like the nose or hair follicles, where it is an effective killer for E. coli (Gläser et al., 2005). 
Psoriasin (S100A7) is strongly induced after toll-like receptor 5 (TLR5) activation by binding flagellin 
from E. coli (Abtin et al., 2008). Furthermore, activation of TLR4 by LPS results in an up-regulation of 
psoriasin (S100A7) and koebnerisin (S100A15) (Büchau et al., 2007). 
 The S100-protein family members are encoded by a single transcript, but with two exceptions: 
S100A4 (Albertazzi et al., 1998; Ambartsumian et al., 1995; Lin et al., 2000) and koebnerisin 
(S100A15). The koebnerisin (S100A15) gene encodes for two alternative splice variants (Wolf et al., 
2003), a short transcript variant, with 0.5 kb, and a long with 4.4 kb (Wolf et al., 2010b). These two 
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transcripts show a different expression in psoriatic skin what assume that they do not share the 
same promotor region.  
 
 
Figure 1.5: Comparison of the amino acid sequence of psoriasin (S100A7) and koebnerisin (S100A15). Same 
amino acids are colored in black, difference in the sequence of psoriasin (S100A7) and koebnerisin (S100A15) 
are colored in orange. N- (amino acids 12-39) and C-terminal (amino acids 54-82) EF-hand motifs are marked 
above the sequence (modified: (Wolf et al., 2010b)). 
 
The primary protein structures of psoriasin (S100A7) and koebnerisin (S100A15) are highly 
homologous and have a conserved C-terminal region and a variant N-terminal region (Figure 1.5) 
(Wolf et al., 2010b). However, the tertiary structure of these S100-proteins is different, psoriasin 
(S100A7) oligomerize zinc dependently, whereas koebnerisin (S100A15) does not despite more than 
90% sequence homology. Psoriasin (S100A7) and koebnerisin (S100A15) regulate through different 
receptors, psoriasin (S100A7) interacts with Receptor of Advanced Glycated End Products (RAGE), 
while koebnerisin (S100A15) acts through a yet unknown Gi-protein-coupled-receptor (GiPCR). Thus 
these S100-proteins have to be discriminated because of their different regulation in tissues and 
cells and there different biochemical characteristics. Additionally both S100-proteins have distinct 
pro-inflammatory functions, e.g. as chemoattractants (Wolf et al., 2010b).  
Psoriasin (S100A7) and koebnerisin (S100A15) are encoded by the S100 gene cluster in the 
epidermal differentiation complex (EDC, chromosome 1q21). In this area, proteins important for 
epidermal maturation and tumorigeneses are encoded. Many proteins are involved in epidermal 
maturation and are encoded in the EDC, such as psoriasin (S100A7), koebnerisin (S100A15), 
involucrin and filaggrin (Mischke et al., 1996). During normal epidermal maturation the terminal 
differentiated keratinocyte layers serve as a physical protection caused by covalent binding of 
protein-complexes that are built by the calcium dependent transglutaminase I (TG) I. S100-proteins, 
consequently psoriasin (S100A7) and koebnerisin (S100A15), are known to be substrates for the 
TGase I (Steinert et al., 1996). Both S100-proteins show a calcium dependent differentiated 
regulation in keratinocytes and expression in healthy skin with normal epidermal maturation 
(Martinsson et al., 2005). 
Koebnerisin    MSNTQAERSIIGMIDMFHKYTGRDG---KIEKPSLLTMMKENFPNFLSACDKKGIH 53 
Psoriasin         MSNTQAERSIIGMIDMFHKYTRRDD---KIDKPSLLTMMKENFPNFLSACDKKGTN 53 
N-terminal EF-hand 
Koebnerisin    YLATVFEKKDKNEDKKIDFSEFLSLLGDIAADYHKQSHGAAPCSGGSQ------- 101 
Psoriasin         YLADVFEKKDKNEDKKIDFSEFLSLLGDIATDYHKQSHGAAPCSGGSQ------- 101 
C-terminal EF-hand 
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In healthy skin, psoriasin (S100A7) is mainly expressed in differentiated cell layers of the epidermis. 
Koebnerisin (S100A15) also shows an expression in non-differentiated keratinocytes, additionally the 
expression of koebnerisin (S100A15) can be detected in melanocytes and Langerhans cells. 
Koebnerisin (S100A15), but not psoriasin (S100A7), can also be detected in endothelial tissue as well 
as in smooth muscle cells of the dermis (Wolf et al., 2010b). Psoriasin (S100A7) and koebnerisin 
(S100A15) are released into the extracellular space, where both proteins act as AMPs against E. coli 
(Büchau and Gallo, 2007; Gläser et al., 2005). Psoriasin (S100A7) is an killer for E. coli (Gläser et al., 
2005). However, koebnerisin (S100A15) also seems to be induced by E. coli and additionally by 
S.aureus and P.aeroginosa, thereby a wide antimicrobial spectrum is anticipated compared to 
psoriasin (S100A7) (Büchau and 
Gallo, 2007) (Figure 1.6a).  
During chronic inflammation the 
expression of psoriasin (S100A7) 
and koebnerisin (S100A15) 
increases and both proteins are 
now distributed to the whole 
epidermis. Inflamed skin is 
characterized by a high number of 
infiltrated immune cells like 
neutrophils, granulocytes or 
macrophages in the dermis and 
epidermis. The infiltrating cells 
express high amounts of pro-
inflammatory cytokines, such as 
IFNγ, IL-12, IL-23 and/or IL-17 
(Numerof and Asadullah, 2006). 
Psoriasin (S100A7) and koebnerisin 
(S100A15) show the same pattern 
of a Th1 but not Th2 induced 
regulation, thus the cytokine-
milieu seems to be important for the S100 protein regulation. Th1 cytokines are found in psoriasis 
and in further chronic inflammatory skin diseases whereas the Th2 milieu is e.g. found in early atopic 
eczema (Grewe et al., 1998). Also lymphocytes expressed Th17 cytokines, like IL-17, are able to 
regulate psoriasin (S100A7), and play an important role in the pathogenesis of psoriasis (Eyerich et 
al., 2009; Sabat et al., 2007). Another function is that psoriasin (S100A7) and koebnerisin (S100A15) 
 
Figure 1.6: Psoriasin (S100A7) and koebnerisin (S100A15) during 
normal epidermal maturation and chronic inflammation. a) Basal 
expression of psoriasin (S100A7) and koebnerisin (S100A15) during 
normal epidermal maturation. Both secreted S100-proteins act as 
antimicrobial peptides. b) Increased expression of psoriasin 
(S100A7) and koebnerisin (S100A15) during inflammation where 
psoriasin (S100A7) and koebnerisin (S100A15) act as 
chemoattractants for leukocytes. (modified: (Zwicker et al., 2012)) 
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act as chemoattractants for leukocytes (Figure 1.6b). However, both S100-proteins have to be 
discriminated in their chemotactic activity: psoriasin (S100A7) is known to activate the multiligand 
receptor RAGE, whereas koebnerisin (S100A15) signals through a yet unknown GiPCR. The activation 
of different receptors may explain the amplified inflammatory response after stimulation with both 
S100-proteins (Wolf et al., 2010b). As a pattern recognition receptor, RAGE is rarely expressed in 
normal tissue but gets up-regulated easily after ligand binding and is, amongst others, responsible 
for leukocyte migration (Ramasamy et al., 2008; Zen et al., 2007).  
To date, very little is known about the regulation of psoriasin (S100A7) and/or koebnerisin 
(S100A15) in keratinocytes, further their role in the pathogenesis of psoriasis is not totally 
understood yet.  
 
1.3 Plaque psoriasis  
Plaque psoriasis is the most common form of psoriasis and affects about 2-3% of the Caucasian 
population (Lowes et al., 2007). Observations on monozygotic and heterozygotic twins show that not 
only the genetic background is responsible for manifestation of psoriasis, also environmental factors 
seem to be involved (Bhalerao and Bowcock, 1998; Monteleone et al., 2011). Until now, genetic 
analysis has identified 19 susceptibility loci on 15 different chromosomes for psoriasis. On the 
PSORS1 locus (psoriasis susceptibility 1), some genes related to psoriasis are encoded, e.g. HLA-Cw6, 
CCHCR1 (coiled-coil α-helical rod protein 1). These proteins have been shown to be highly up-
regulated in psoriasis (Nair et al., 2006) and seems to be important for the differentiation of 
keratinocytes (Allen et al., 2001). Furthermore, a variant of the HLA-C-gene, HLA-Cw0602, which 
encodes a MHC I protein, is related to early chronic psoriasis (Asumalahti et al., 2000; Fan et al., 
2008; Nair et al., 2006). Most of the S100-proteins are encoded within the recombinant region of 
S100 gene clusters on the psoriasis susceptibility locus 4 (PSORS4, Epidermal Differentiation 
Complex, chromosome 1q21) therefore, psoriasin (S100A7) and koebnerisin (S100A15) are 
considered disease candidate genes (Hardas et al., 1996; Semprini et al., 1999; Semprini et al., 2002). 
Up-regulated in non-lesional skin, both S100-proteins might be involved in the disease susceptibility 
of psoriasis (Wolf et al., 2010a). Non-lesional psoriatic skin induces a strong local inflammation upon 
inflammatory or mechanical trigger and is called koebner phenomenon.  
Plaque psoriasis is an inflammatory skin disease and molecular characterized by a dysregulated 
interaction between keratinocytes and infiltrating inflammatory cells (Lowes et al., 2007; Nickoloff, 
2006). In the epidermis Langerhans cells are permanently located, these cells are a subpopulation of 
epidermal dendritic cells the most important antigen presenting cells (APC), and act as a link 
between the innate and adaptive immune system. Beside in the epidermis, also in the dermis 
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specialized DCs could be found (myeloid and plasmacytoid DCs) (Zaba et al., 2009). Under healthy 
conditions, LCs absorb particles of the epidermis and get activated by exogenous and/or 
endogenous stimuli, such as allergens or microbes. However, psoriasis can be manifest by different 
triggers e.g. a trauma (Nickoloff, 2007). After activation, LCs up-regulate chemokine-receptors and 
migrate actively into the draining lymph nodes. In the lymph node LCs present parts of peptides to 
naïve T cells that get activated after binding (Merad et al., 2008; Zaba et al., 2009). An increased 
number of CD11c+ myeloid DCs during inflammation can be observed, these cells are attracted by 
chemotactic signals and produce high amounts of pro-inflammatory cytokines like IL-12, IL-23 and 
TNFα (Merad et al., 2008; Nestle et al., 2009a; Zaba et al., 2009). Not only DCs but also the amounts 
of macrophages are highly increased in lesional psoriatic skin. Several studies showed, that besides 
secreting IL-6, IL-12 and IL-23 macrophages are important inducers of TNFα (Sabat et al., 2007; 
Yawalkar et al., 2009). 
Also keratinocytes produce an increased amount of different pro-inflammatory cytokines as well as 
AMPs, such as hβD (human-β- defensin) and LL-37 (cathelicidin) and chemotactic cytokines, like IL-8 
(Gilliet and Lande, 2008; Nestle et al., 2009a). The main source of IL-12 and IL-23 in psoriatic skin are 
activated DCs, neutrophils and macrophages (Kastelein et al., 2007), these cytokines induce further a 
Th1 cytokine development (Hsieh et al., 1993). Despite IL-12 and IL-23 belong to the same cytokine 
family, their functions are different. Whereas IL-12 induces mainly IFNγ thus a Th1 cytokine-milieu, 
IL-23 regulates Th17 cells which express IL-17 and IL-22 (Reiner, 2007).  
IL-1β is a key player in cutaneous inflammation and promotes the development of the Th17 micro-
milieu in psoriasis. Th1/Th17-differentiated immunocytes in the skin are crucial for psoriasis 
pathogenesis (Johansen et al., 2007; Nestle et al., 2009b). Recent studies reveal that NALP1 gene 
variants confer susceptibility to combinations of skin-associated auto-inflammatory and 
autoimmune diseases, including vitiligo, rheumatoid arthritis, autoimmune thyroid disease and type 
1 diabetes (Dwivedi et al., 2013; Jin et al., 2007; Pontillo et al., 2012). In the skin, the expression of 
NALP1 specific caspase-5 has been shown to correlate with Th17-mediated chronic inflammatory 
diseases, such as psoriasis, a pattern consistent with the involvement of the NALP1 inflammasome in 
IL-1β-mediated skin auto-immunity and auto-inflammation (Gregersen, 2007; Martinon and 
Tschopp, 2004; Salskov-Iversen et al., 2011). 
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 Such a Th1/Th17 cytokine-milieu is typical for psoriasis and promotes the inflammation like a vicious 
circle (Nestle et al., 2009a). Keratinocytes are activated to produce and secrete pro-inflammatory 
cytokines and AMPs that act as chemoattractants for leukocytes and neutrophils (Wolf et al., 2008; 
Wolf et al., 2010a). The vicious circle develops because the expression and secretion of pro- 
inflammatory cytokines like TNFα, IL-1β, IFNγ and multifunctional S100-proteins amplify the skin 
inflammation (Sa et al., 2007) (Figure 1.7).  
1.3.1 Therapy of psoriasis 
In psoriasis, treatment options depend on the severity of the disease. For more than twenty years 
vitamin D-analogs, such as calcipotriol, are used very successful in mono-therapy as well as in 
combination with corticosteroids for topical treatment. The inactive vitamin D3, also called calciol, is 
the precursor of the biologic active 1α.25-dihydroyvitamin D3 (1.25(OH)2D3), a vitamin D metabolite 
that develops of 7-dehydrocholesterol (7-DHC) after UVB irradiation in the human skin. Not all of the 
vitamin D needed can be produced in the skin, about 20% has to be absorbed by food (Holick, 2007; 
Tremezaygues et al., 2009).  
 
Figure 1.7: Schematics of different cell types and cytokines important during inflammation in psoriasis. A 
genetic background and many environmental factors are important to induce psoriatic lesions. Langerhans cells 
(LC) in the epidermis are activated and migrate to their draining lymph node and activate naïve T cells. 
Macrophages (Mφ) and dermal DCs (dDCs) also get activated and express and secrete different pro-
inflammatory cytokines like TNFα, IL-23 and IL-12. While IL-12 is responsible for inducing IFNγ producing Th1 
cells IL-23 is responsible for inducing IL-17 and IL-22 producing Th17 cells. This Th1/Th17 cytokine-milieu is 
typical for psoriasis. The expressed pro-inflammatory cytokines activate keratinocytes and induce a 
keratinocyte hyperplasia. Recruited by chemoattractants an increased number of neutrophils induce a positive 
feed-back-loop which amplifies the inflammation (Modified: (Nickoloff, 2007)).  
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The biologic active form of vitamin D3, (1.25(OH)2D3), binds to the intracellular vitamin D-receptor 
and induces target genes. Similarly, vitamin D-analogs bind to the vitamin D-receptor and induce the 
corresponding target genes (Dusso et al., 2005; Nagpal et al., 2005). The vitamin D-receptor belongs 
to the steroid-hormone-receptor super-family and is expressed constitutively in keratinocytes or can 
be induced e.g. in T cells. The primary anti-psoriatic effect is caused by the reduced proliferation and 
induction of genes that have a positive impact on differentiation like involucrin, loricin or 
transglutaminase in keratinocytes (Nagpal et al., 2005; White, 2004). The secondary anti-psoriatic 
effect is based on the immunomodulation: the T cell activation is inhibited and regulatory T cells are 
induced, whereas the maturation of DCs is inhibited after treatment with vitamin D or its analogs 
(Holick, 2007; Van Etten et al., 2003). In addition to the immunomodulatory effect on different cell 
types, vitamin D and its analogs, also induce AMPs, like cathelicidin, in the skin (Gombart et al., 2005; 
Wang et al., 2004; Weber et al., 2005). Calcipotriol treated skin of patients with psoriasis show a 
down-regulation of the pro-inflammatory cytokines IL-17A and IL-8 (Peric et al., 2009). 
Besides topic therapy, moderate to serve psoriasis is treated systemically by so called ‘biologics’. 
Biologics are defined as drugs, vaccines or antitoxins, which are synthesized from living organisms or 
their products and are used as diagnostic, preventive or therapeutic agent (American Heritage®). 
Recombinant fusion proteins or monoclonal antibodies are used for systemically treatment of 
psoriasis. Etanercept is a TNFα blocker used for treatment of patients with moderate to serve 
psoriasis. This recombinant human TNF receptor fusion protein antagonizes endogenous TNFα 
because of its higher affinity of Etanercept compared to the TNF-receptor (Mease et al., 2000). The 
therapeutic effect could be proven in multiple clinical studies (Gottlieb et al., 2003; Leonardi et al., 
2003). A different biologic is Ixekizumab, a humanized IgG monoclonal antibody that selectively 
binds and neutralizes IL-17A. It blocks the production of cytokines and AMPs (Leonardi et al., 2012; 
Martin et al., 2013), Ixekizumab is successfully tested in clinical studies trail II phase (Leonardi et al., 
2012). 
 
1.4 Aims 
Psoriasin (S100A7) and koebnerisin (S100A15) in skin homeostasis 
The multifunctional proteins psoriasin (S100A7) and koebnerisin (S100A15) are mainly expressed in 
the epidermis and are linked to maturation. As part of the cornified envelope and as antimicrobial 
peptides, both S100-proteins protect the skin for mechanical and biological damage. Despite their 
high homology psoriasin (S100A7) and koebnerisin (S100A15) are different in expression and 
function. Little is known about the expression of both S100-proteins in dermal- and immune-cells 
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that are involved in skin immunity. My working hypothesis is that psoriasin (S100A7) and koebnerisin 
(S100A15) are further expressed by non-epithelial cells.  
The objective is to analyze leukocytes, monocytes, neutrophils and fibroblasts as a possible source of 
psoriasin (S100A7) and koebnerisin (S100A15). This is important because these cells are key actors 
during chronic and acute skin inflammation. The impact of psoriasin (S100A7) and koebnerisin 
(S100A15) expands in inflammation when expressed by circulating immune cells. 
 
Regulation of psoriasin (S100A7) and koebnerisin (S100A15) in inflammation 
Psoriasin (S100A7) and koebnerisin (S100A15) were discovered up-regulated in chronic psoriasis, a 
Th17-mediated inflammatory skin disease. Also in acute inflammation, e.g. after UVB irradiation, an 
up-regulation of both S100-proteins has been described. Little is known about the capacity of the 
chronic Th17-mediated cytokine-milieu and the environmental influence of acute UVB irradiation to 
regulate these S100-proteins. My working hypothesis is that endogenous and exogenous factors 
regulate psoriasin (S100A7) and koebnerisin (S100A15) expression in the skin.  
The objective is to analyze the S100-regulation in the in vitro models of chronic and acute 
inflammation. This is important because regulation of psoriasin (S100A7) and koebnerisin (S100A15) 
implicates a functional relevance of these S100-proteins for skin inflammation.  
 
Function of psoriasin (S100A7) and koebnerisin (S100A15) during inflammation 
Besides psoriasin (S100A7) and koebnerisin (S100A15) also a key player for inflammation, IL-1β, is 
up-regulated in chronic inflammatory skin diseases and promotes the development of the Th1/Th17 
micro-milieu. The biological activity of IL-1β is regulated on transcriptional level, through IL-1β-
processing inflammasomes. IL-1β activating inflammasome complexes are described in skin, but little 
is known about the mechanisms of their regulation and activation for epidermal IL-1β release. My 
working hypothesis is that that psoriasin (S100A7) and koebnerisin (S100A15) act as pro-
inflammatory ‘alarmins’ and as novel regulators for inflammasome activity and IL-1β release in 
human skin. 
The objective is to analyze inflammasome regulation and activation dependent on S100-expression 
in human epidermal keratinocytes. This is important because the functional relevance of psoriasin 
(S100A7) and koebnerisin (S100A15) indicates for targets to develop therapeutic approaches for 
inflammatory skin diseases. 
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Anti-inflammatory function of vitamin D on psoriasin (S100A7) and koebnerisin (S100A15) in 
chronic inflamed psoriatic skin 
Psoriasin (S100A7) and koebnerisin (S100A15) are up-regulated in chronic inflamed skin and act as 
chemoattractants for leukocytes and have further immune regulatory functions. Vitamin D and its 
analogs are successfully used as a topical treatment for moderate psoriasis, but the underlying 
mechanism is not completely understood. My working hypothesis is that vitamin D acts anti-
inflammatory by down-regulating psoriasin (S100A7) and koebnerisin (S100A15) in chronic inflamed 
skin.  
The objective is to analyze the mechanism of vitamin D on psoriasin (S100A7) and koebnerisin 
(S100A15) expression in chronic inflamed skin, and to analyze the anti-inflammatory mechanism in 
human epidermal keratinocytes. This is important because suppression of both S100-proteins by 
vitamin D may provide new therapeutic possibilities for other pro-inflammatory diseases with an 
increased psoriasin (S100A7) and koebnerisin (S100A15) expression. 
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2. Materials and Methods 
 
2.1 Materials 
2.1.1 Technical devices 
In table 2.1, all used devices and their manufacturer are listed. 
Table 2.1: Used technical devices 
devices manufacturer 
sterile bench LaminAir (Burgdorf; Switzerland) 
incubator (HeraCell) Heraeus (Düsseldorf; Germany) 
incubator (HeraCell 150i) Heraeus (Düsseldorf; Germany) 
Biofuge fresco Heraeus (Düsseldorf; Germany) 
Megafuge 2.0 R Heraeus (Düsseldorf; Germany) 
Nanophotometer Implen (Munich; Germany) 
RealTime C1000 Thermal Cycler BioRad (Munich; Germany) 
Veriti 96 well Thermal cycler Applied Biosystems (Darmstadt; Germany) 
Microscope, Axiovert25  ZEISS (Jena; Germany) 
Microscope, ImagerZ1 ZEISS (Jena; Germany) 
ELISA-Reader Spectra MR  Dynex technologies (Denkendorf; Germany) 
ultraviolet B lamp TL20W/12RS Philips (Amsterdam; Netherlands) 
Gel Documentation  Biometra GmbH (Göttingen; Germany)  
Cell homogenizer bertin technologies (Montigny-le-Bretonneux; France) 
 
2.1.2 Plastic consumables 
If not specially mentioned, all plastic consumables like cell culture flask and multi-well-dishes, cell 
scraper, serological pipettes and reactions tubes were obtained from TPP (Techno Plastic Products 
Ltd.) (Zürich; Switzerland), Santa Cruz Biotechnology Inc. (Heidelberg; Germany), Greiner Bio One, 
(Frickenhausen; Germany) and Biozym Scientific GmbH (Oldendorf; Germany).  
2.1.3 Cells, medium, buffer & solutions 
HEK (Human epidermal keratinocytes) (Invitrogen life technology, Darmstadt; Germany) were 
cultured in keratinocyte specific Epilife® media with supplements EDGS and antibiotics. 
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Table 2.2: Used media for cell culture and their appendant supplement 
media supplements manufacturer 
 
Epilife® medium 
 
Epilife defined growth supplement (EDGS) 
Gentamicin/ Amphotericin 
Gibco life technology 
(Darmstadt; Germany) 
transfection 
medium 
no 
Gibco life technology 
(Darmstadt; Germany) 
 
The following buffers and solutions were used: 
-PBS  137 mM NaCl (sodium chloride) 
2.7 mM KCl (potassium chloride) 
80.9 mM Na2HPO4 (disodium hydrogen phosphate) 
1.5 mM KH2PO4 (potassium dihydrogen phosphate) 
pH= 7.4 
 
- TBS-T  50 mM Tris/HCl, pH=7.6 
150 mM NaCl 
0,1% Tween 20 
 
- DEPC H2O 0.1% DEPC in aqua dest. Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
 
- Trypan blue 1:10 in PBS   Sigma-Aldrich, Steinheim; Germany 
2.1.4 Antibodies, primers & siRNAs 
All used primers were designed with the free online portal Universal ProbeLibrary from Roche. All 
primers were tested additionally of dimers and hairpins and were blasted to the whole human 
genome by Primer-BLAST.   
 
Table 2.3: The following antibodies were used for Western blot (WB) and immunofluorescence (IF) 
staining analysis 
primary antibody dilution clone manufacturer 
anti-IL-1β 
1:200 (WB) 
H-153 
Santa Cruz Biotechnology Inc. (Heidelberg; 
Germany) 
anti-IL-1β 
1:1000 (WB) 
1:50 (IF) 
 Cell Signaling Technology (Danvers, MA; USA) 
anti-caspase-1 1:1000 (WB)  Cell Signaling Technology (Danvers, MA; USA) 
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anti-caspase-5 
1:1000 (WB) 
1:50 (IF) 
 Cell Signaling Technology (Danvers, MA; USA) 
anti-β-actin 1:2000 (WB) 13E5 Cell Signaling Technology (Danvers, MA; USA) 
anti-NF-κB p65 1:400 (IF) E498 Cell Signaling Technology (Danvers, MA; USA) 
anti-psoriasin 
(S100A7) 
1:500 (WB) 
1:100 (IF) 
47C1068 Abcam® (Cambridge; UK) 
anti-koebnerisin 
(S100A15) 
1 µg/ml 
 
 Customized (Wolf et al., 2008) 
anti-α-tubulin 
1:10000 
(WB) 
 Abcam® (Cambridge; UK) 
anti-IL-17A  4 µg/ml (IF) 133617 R&D Systems, Minneapolis, MN; USA 
secondary 
antibody 
 conjugate manufacturer 
goat anti-rabbit 
IgG 
1:250 (IF)  Alexa Fluor® 
647 
Invitrogen life technology (Darmstadt; 
Germany)  
 
 1:10.000 
(WB) 
 Cell Signaling Technology (Danvers, MA; USA) 
goat anti-mouse 
IgG 
1:250 (IF) Alexa Fluor® 
488 
Invitrogen life technology (Darmstadt; 
Germany) 
 1:10.000 
(WB) 
 
Cell Signaling Technology (Danvers, MA; USA) 
 
Table 2.4: Forward and reverse primer pair sequences that were used  
gene forward reverse 
AIM2 aaa ccc ttc tct gat aga ttc ctg cac caa aag tct ctc ctc atg tta 
caspase-1 atg cct gtt cct gtg atg tg ctc ttt cag tgg tgg gca tc 
caspase-5 gga caa acc caa ggt cat ca aga tga ctg tga aga gat gac tgc 
IL-1β tac ctg tcc tgc gtg ttg aa tct ttg ggt aat ttt tgg gat ct 
IL-6 cag gag ccc agc tat gaa ct gaa ggc agc agg caa cac 
IL-8 gct cta gaa tga ctt cca agc tgg ccg cgg gat cct tat gaa ttc tca gcc ctc t 
NALP1 cat cct gcc tgc aaa ctc a cct cag ttc ctg cct cat ct 
NALP3 ggc tgt aac att agg aga ttg agg gcg ttgtca ctc agg t 
RAGE gct cat tgg ggt cat ctt gt ctg agg cca gaa cag ttc aa 
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PBGD tgc ata taa tct ctt gtt ctc acc a ggg cca tct tca tgc tgt at 
RNase7 gaa gac caa gcg caa agc agc aga agg ggg cag aat 
S100A15L acg tca ctc ctg tct ctc ttt gct tga tga atc aac cca ttt cct ggg 
S100A15S caa gtt cct tct gct cca tct tag agc ctt cag gaa ata aag aca atc 
S100A7 aga cgt gat gac aag att gac tgt cct ttt tct caa aga cgt c 
TNFα gac aag cct gta gcc cat gt tct cag ctc cac gcc att 
hβD2 ggg gct cct tca taa gtg ttt gga gaa gca ccg agt agg g 
 
Table 2.5: Used siRNA sequences and the starting position in the gene 
siRNA_position sequence efficacy ±SD (p value) 
non-sensing control 5’-cgc gua agg ucg aau gca uaa tt-3’  
caspase-1_121 5’-gaa gac uca uug aac aua utt -3’ 0.153 ± 0.062 (p<0.0001) 
caspase-5_788 5’-cca ccu aau gga aau auu utt-3’ 0.523 ± 0.275 (p<0.0001) 
NALP1_1470 5’-gga gaa ucg agg aca uuu att-3’ 0.563 ± 0.168 (p<0.0001) 
NALP3_194 5’-aug ugg acu uga aga aau utt-3’ 0.317 ± 0.136 (p<0.0001) 
S100A7_112 5’-gac aug uuu cac aaa uac att-3’ 0.037 ± 0.027 (p<0.0001) 
S100A15 5’-uac uuc uuc ugu cuc auu att-3’ 0.415 ± 0.240 (p<0.05) 
 
2.1.5 Chemicals, reagents & stimulants 
Chemicals 
Ethanol     Sigma-Aldrich, Steinheim; Germany 
Methanol    MERCK, Grafing, Germany 
Chloroform    Invitrogen life technology, Darmstadt; Germany 
Trizol®     Invitrogen life technology, Darmstadt; Germany 
Tween 20    Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Sodium hydroxide   Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Hydrochloric acid   Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Milk powder, fat free   Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Trypan blue    Sigma-Aldrich, Steinheim; Germany 
DMSO (Dimethyl sulfoxide)  Sigma-Aldrich, Steinheim; Germany 
 
Stimulants 
S100A7  10-10000 ng/ml produced by Dr. Ronald Wolf  
S100A15 10-10000 ng/ml produced by Dr. Ronald Wolf  
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(National Institute of Health, Bethesda, MD; USA) 
IL-17α  10 ng/ml  R&D Systems, Minneapolis, MN; USA 
IL-22  10 ng/ml  R&D Systems, Minneapolis, MN; USA 
TNFα  50 ng/ml  Biomol, Hamburg; Germany 
IFNγ  100 ng/ml  Biomol, Hamburg; Germany 
poly(dA:dT) 1 µg/ml  Sigma-Aldrich, Steinheim; Germany 
UVB  10-30 mJ/cm2  Philips (Amsterdam; Netherlands) 
2.1.6 Kits 
IL-1β ELISA DuoSet    R&D Systems, Minneapolis, MN; USA 
Quick-RNA™ MiniPrep    HISS Diagnostics, Freiburg; Germany 
cDNA Synthesis Kit    Finnzymes, Espoo; Finland 
BCA™ Protein Assay Kit   Thermo Fisher Scientific, Bonn; Germany 
2.1.7 Western blot consumables 
Membranes, films and developer for Western blot analysis were obtained from GE Healthcare 
(Munich; Germany) and Thermo Fisher Scientific (Bonn; Germany). 
2.1.8 Software 
GraphPad Prism 5.0   Statistical analysis 
Spectra MR   ELISA analysis 
BioDocAnalyze   Western blot analysis 
BioRad CFX manager 3.0 Analysis of qPCR runs 
EndNote X4   Citation 
 
2.2 Methods 
2.2.1 Patients and skin samples 
All sample acquisitions were approved by the local ethics committee (Faculty of Medicine, Ludwig-
Maximilian University, Munich; Germany). The study was conducted in according with the 
Declaration of Helsinki Principles. For all the procedures, informed patients’ written consent was 
obtained. Lesional and non-lesional skin biopsies of Caucasian individuals (age = 22–56 years) were 
examined and compared to healthy skin. The tissues were subjected to RNA extraction or snap 
frozen in liquid nitrogen for immunofluorescence staining (see below). 
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2.2.2 Cell culture and stimulation 
Cell culture 
Human epidermal keratinocytes were grown in EpiLife® cell culture medium with 0.06 mM calcium 
(Invitrogen life technology) supplemented with human keratinocyte EpiLife® defined growth serum 
(100x) (Invitrogen life technology) and 10 µg/ml gentamicin and 0.25 µg/ml amphotericin B 
(Invitrogen life technology), and cultured in a humidified atmosphere of 5% CO2 at 37
oC. Cells in the 
logarithmic growth phase were used in all experiments. Stock cultures were maintained for up to 
four passages in the culture medium. 
 
Cells storage 
30.000 to 40.000 cells from passage one to three were frozen in 1 ml EpiLife® medium with 10% 
DMSO (Dimethyl sulfoxide) (Sigma) in liquid nitrogen.  
To unfreeze the cells, cryo-tubes with cells were heated in a water bath to 37°C and immediately 
transferred to a 75 cm2 culture flask filled with 9 ml media. After two hours, the media were 
changed. 
 
Keratinocyte stimulation 
Cells reaching approximately 60-80% of confluence were stimulated with TNFα (50 ng/ml; Biomol), 
IFNγ (100 ng/ml; Biomol), IL-17A (10 ng/ml; R&D Systems), S100A7 (100 ng/ml) and/or S100A15 (100 
ng/ml) for 24 hours. After an incubation of 6 hours the same cells were transfected with 1 µg/ml 
DNA (Sigma) and after 18 hours incubation cell supernatants and total protein or RNA were collected 
for further investigations.   
2.2.3 RNA-isolation and cDNA synthesis 
RNA isolation kit in columns (Zymo research) 
Total cellular RNA of cell culture was isolated from human epidermal keratinocytes (Quick-RNA 
MiniPrepTM; HISS Diagnostics) according to the manufacturer’s protocol: after removing the cell 
culture supernatants 600 µl lyses buffer per 12-well were added. Cells with lyses buffer were 
scratched in the plate and each well transferred into a single column. Isolation of RNA was 
performed in accordance with the manufacturer’s protocol (Zymo research, Quick-RNA MiniPrepTM). 
 
RNA-isolation with Trizol® 
Media from cells in a 12-well plate were removed, collected and stored at -20°C, afterwards cells 
were washed with 1 ml PBS. To homogenize the cells 1 ml Trizol® reagent per well was added and 
incubated for 5 min at room temperature, meanwhile mixed thoroughly by pipetting, homogenized 
solution was transferred into a new 1.5 ml tube. For phase separation 0.2 ml chloroform were added 
per tube and shacken in the hands for 15 sec, afterwards incubated at room temperature for 3 min. 
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After the incubation time cells were centrifuged with 12.000 g for 15 min and 4°C, three phases were 
visible and in the first phase provided the RNA, the last one provided DNA and proteins. From the 
first phase 0.2 ml were transferred to a new tube two times and 0.5 ml Isopropanol were added and 
shacken softly in the hands. After 10 min incubation at room temperature tubes were centrifuged 
with 12.000 g for 10 min at 4°C. On the bottom of the tube the gel-like RNA pellet  was situated. The 
supernatant was discarded and 1 ml 75% ethanol were added, vortexed and centrifuged with 7.500 
g for 5 min and 4°C. Again the supernatant was discarded and for 5 – 10 min the RNA dried, per tube 
25 µl RNase free water was added and pipetted until the RNA dissolved in the water. Like this, 
probes could be stored in the -80°C. 
 
RNA isolation from tissue 
Tissue was cut into small pieces and transferred into a 2 ml precellys-ceramic 2.8 mm tube (Peqlab) 
that was filled with 1 ml Trizol® (Invitrogen life technology). Tubes were homogenized with precellys 
24 lysis & homogenization (bertin technologies) 6200 rpm for 20 sec. After every run the tubes were 
cooled down on ice for 3 min. After three repeats Trizol® with tissue pieces was transferred into a 
new 1.5 reaction tubes and continued like described in the isolation with Trizol®, see above. 
 
cDNA synthesis 
Subsequently, 1 µg RNA was reversely transcribed using DyNAmo complementary DNA Synthesis Kit 
(Finnzymes) as described by the supplier.  
The following master mix was used for every probe: 
 
Table 2.6: Reaction setup for cDNA synthesis 
volume components 
10 µl 2x RT buffer (including dNTP mix and 10 mM MgCl2) 
2 µl M-MuLV RNase H+ RT (reverse transcriptase) 
1 µl Oligo (dT)15 primer (100 ng/µl) 
X µl template RNA (max 1 µg) 
X µl RNase free water until the final reaction volume 
 total volume of 20 µl 
 
Table 2.7: Incubation protocol for reverse transcriptase 
temperature time comments 
10 min  25°C Primer extension 
30 min  37°C cDNA synthesis 
5 min   85°C reaction termination 
∞ 4°C  cooling samples 
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2.2.4 Real-time-PCR (qPCR) 
Complementary DNA was analyzed by SYBR Green supermix in CFX96-real-time detection system 
(Bio-Rad Laboratories, Hercules, CA, USA), using the sequences of primers presented in Table 1. 
Relative expression of the genes was calculated with the ΔCT method (Wolf et al., 2009), with the 
elongation of β-actin (Qiagen) or PBGD gene used as housekeeping genes. All analyzes were carried 
out in triplicates per condition, using three independent cell stimulation experiments. 
 
Table 2.8: Standard running qPCR protocol 
step temperature time comments 
1 95°C 30 sec  
2 95°C 5 sec  
3 60 5 sec reading plate 
4   repeat step 2-3 50 times in total 
5   Melt curve from 65°C to 95°C in 0.5°C steps 
 
2.2.5 siRNA design and transfection 
siRNA design 
Table 2.9:  Criteria and score for siRNA design (Reynolds et al., 2004). 
Criteria Description 
Score 
Yes No 
1 moderate to low (30-52%) GC content 1 point  
2 at least 3 A or U at position 15-19 1 point per A or U  
3 lack of internal repeats 1 point  
4 A at position 19 1 point  
5 A at position 3 1 point  
6 U at position 10 1 point  
7 no G or C at position 19  - 1 point 
8 no G at position 13  - 1 point 
 
siRNA transfection 
Primary human keratinocytes reaching 60-70% of confluence were transfected with 5 nM siRNA 
oligonucleotides with RNAiMAX transfection reagent (Invitrogen life technology), for RNA analysis 
12-well plates with 0.5 ml total volume and for protein analysis 6-well plates with 1 ml total volume 
were used. For every well 62.5 µl OPTI-MEM reduced serum medium (Invitrogen life technology) and 
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0.5 µl  (12-well) or 1 µl (6-well) DNA (1 µg/ml) were slightly mixed in a 1.5 reaction tube, at the same 
time a second 1.5 reaction tube with 62.5 µl OPTI-MEM reduced serum medium and 0.625 µl 
RNAiMAX transfection reagent was prepared. After incubation for 5 min at room temperature 
contents of both tubes were slightly mixed by pipetting and incubated for 20 additionally min more 
at room temperature. Every well was filled up with 375 µl EpiLife® cell culture medium with 0.06 
mM calcium and 125 µl siRNA solution. Cells were transfected with caspase-1, caspase-5, NALP1, 
NALP3, psoriasin (S100A7), koebnerisin (S100A15) or non-target control siRNA for 48 hours.  
Subsequently, cells were stimulated as described earlier, either harvested for RNA or protein 
analysis. 
2.2.6 Protein isolation and Western blot 
Protein isolation from cell culture 
Primary human keratinocytes were stimulated in 6-well plates and 1 ml of medium as described 
before (see chapter 2.2.2 Keratinocyte stimulation). The supernatants of every protein probes were 
collected in 2 ml tubes and stored at -80°C. Cells in the plates were lysed with T-PER buffer with 
complete mini, a 7x protease inhibitor (Roche, Mannheim; Germany), and PMSF 
(phenylmethylsulfonyl fluoride) a 200x serine protease inhibitor (200 nm), and scratched. Cell debris 
and buffer were transferred to a 1.5 reaction tube, vortexed and incubated on ice for 30 min. After 
incubation, tubes with protein and cell debris were centrifuged with 13000 g for 20 min at 4°C. The 
soluble proteins were in the supernatant, which was transferred to a new 1.5 ml reaction tube. 
Proteins were stored at -80°C. 
 
Protein isolation from tissue 
Tissue was cut into small pieces and transferred into a 2 ml precellys-ceramic 2.8 mm tube (Peqlab) 
that was filled with 400 µl T-PER buffer Tubes were homogenized (Precellys 24 lysis & 
homogenization, bertin technologies) with 6200 rpm for 20 sec. After every run the tubes were 
cooled down on ice for 3 min. After three rounds T-PER buffer was transferred into a new 1.5 ml 
reaction tubes, additionally rinsed with 100 µl buffer. Protein isolation was performed as described 
in the previous section (2.2.6 Protein isolation from cell culture). 
 
Protein precipitation  
A defined volume (1.5 ml) of stimulated cell culture supernatants were precipitated with 10% total 
volume of 100% trichloroacetic acid, vortexed and incubated for 20 min on ice. After additionally 
vortexing, the probes were centrifuged with 13.000 rpm at 4°C for 15 min. The supernatant were 
refused and the pellets washed with 1 ml of cool acetone. The washed proteins were centrifuged 
with 13.000 rpm at 4°C for 10 min, again a white pellet has to be seen. The pellets were solved in 
protein buffer (see protein isolation). 
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Western blot 
Lysates and supernatants of cultured keratinocytes as well as skin samples (15-25 µg) were 
prepared, using T-PER Tissue Protein extraction lyses buffer (Thermo Fisher Scientific). Proteins were 
separated using a 12% SDS-polyacrylamid gel, transferred to reinforced nitrocellulose membranes 
and incubated with blocking buffer (Tris buffered saline, pH 7.5, 0.1% Tween 20 (TBS-T), 5% milk 
powder) for 60 min at room temperature. The membrane was incubated overnight at 4oC with the 
respective specific primary antibodies diluted in 5% BSA/TBS-T: anti-caspase-1 IgG (1:1000) and anti-
caspase-5 IgG (1:1000). Followed by washing three times with TBS-T, blots were developed by 
incubation with horseradish-peroxidase-conjugated IgGs (1:10.000) for 1 hour at room temperature 
and visualized with chemiluminescence method following the manufacturer’s protocol (Thermo 
Fisher Scientific). Gel loading was controlled by detecting α-tubulin signal with monoclonal 
antibodies (Abcam plc; 1:10.000).  
2.2.7 ELISA 
Primary human keratinocytes were pre-stimulated for 6 hours with IFNγ (100 ng/ml; Biomol), TNFα 
(50 ng/ml; Biomol), IL-17A (10 ng/ml; R&D Systems) and/or psoriasin (S100A7) (100 ng/ml) and 
additionally transfected with poly(dA:dT) (1 µg/ml; Sigma–Aldrich) or irradiated with UVB light (10 – 
30 mJ/cm2; Philips). The supernatants were collected and analyzed for secreted IL-1β by ELISA assay 
according to the manufacturer’s protocol (IL-1β ELISA Duo Set; R&D Systems). 
2.2.8 Immunofluorescent staining 
Immunofluorescence staining was performed on serial frozen sections (d=8 µm) of human healthy 
and psoriatic skin fixed for 5 min in -20oC acetone. The sections were blocked for one hour in 10% 
normal goat serum/3%BSA/PBS, and incubated overnight with rabbit anti-human caspase-5 (1:50 
Cell Signaling), rabbit anti-human caspase-1 (1:50; Cell Signaling), mouse anti-human psoriasin 
(S100A7, 10 µg/ml; Abcam) or rabbit anti-human koebnerisin (S100A15; 5 µg/ml (Wolf et al., 2008)). 
The sections were further incubated with goat anti-rabbit IgG conjugated with Alexa Fluor® 647 or 
Alexa Fluor® 488 (1:250; Invitrogen life technology) and diluted in 10% normal goat 
serum/3%BSA/PBS and incubated for 1 hour at room temperature in a dark humidified chamber. 
Staining with secondary antibodies only was performed as a negative control. Sections were overlaid 
with ProLong Gold antifade reagent containing DAPI (Invitrogen life technology). Fluorescent stained 
tissues were imaged using a 12-bit CCD digital camera PCO PixelFly (PCO) or by a fluorescent 
microscope Zeiss ImagerZ1 (Zeiss). 
 
Chamber slide 
Keratinocytes were cultivated on a chamber slide and stained as described before. 
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2.2.9 Statistical analysis 
All statistical analyzes were performed using GraphPad Prism 5.01 software (La Jolla, CA, USA). 
Student´s t test and ANOVA were used to calculate statistical differences. Values of p < 0.05 = *; p < 
0.01 = **; p < 0.001 = *** were considered significant and all data are displayed as means ± SD or 
SEM as indicated.  
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3. Results 
 
 
3.1 Psoriasin (S100A7) and koebnerisin (S100A15) in skin homeostasis 
 
The high homolog S100-proteins psoriasin (S100A7) and koebnerisin (S100A15) are part of the 
cornified envelope and covalent linked by transglutaminase I (TGaseI). Both S100-proteins are 
calcium dependent regulated, thus involved in epidermal maturation and part in the process of 
cornification (Steinert et al., 1996). When secreted, psoriasin (S100A7) and koebnerisin (S100A15) 
act as antimicrobial peptides (AMPs), with different characteristics. Psoriasin (S100A7) as well as 
koebnerisin (S100A15) are induced by E. coli whereas koebnerisin (S100A15) is additionally induced 
by S. aureus and P. aeroginosa and the spectrum as AMP might be larger (Büchau et al., 2007). 
Psoriasin (S100A7) can be found in areas that are highly colonized with bacteria like the nose or hair 
follicles (Gläser et al., 2005), thus both S100-proteins are important for skin protection. 
3.1.1 Psoriasin (S100A7) and koebnerisin (S100A15) have different expression patterns in healthy skin  
Psoriasin (S100A7) and koebnerisin (S100A15) are constitutively expressed in healthy skin. However, 
no expression of psoriasin (S100A7) could be measured in the basal- or in deeper skin layers like the 
dermis. But the expression of psoriasin (S100A7) was increased with the stadium of differentiation in 
keratinocytes, thus the psoriasin (S100A7) expression correlates with the keratinocyte 
differentiation (Figure 3.1a). Koebnerisin (S100A15) was mainly expressed in the basal layer of the 
epidermis as well as in the dermis, thus this S100-protein showed a different distribution pattern in 
healthy skin compared to the highly homologous psoriasin (S100A7) (Figure 3.1b).  
To investigate the expression of both S100-proteins in the dermis, normal skin-derived fibroblasts 
were cultivated on a chamber slide and immunofluorescent stained for psoriasin (S100A7, green) 
and koebnerisin (S100A15, red). Whereas expression of koebnerisin (S100A15, red) could be 
detected, psoriasin (S100A7, green) was not expressed (Figure 3.1c and d). 
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Figure 3.1: Psoriasin (S100A7) and koebnerisin (S100A15) are distinguished expressed in healthy skin cells. 
Immunofluorescent staining of frozen sections of normal skin stained for (a) psoriasin (S100A7, green) and (b) 
koebnerisin (S100A15, red), nuclei were stained with DAPI (blue). Staining represent one of three 
independent experiments. Scale bar = 50 µm. Immunofluorescent staining of fibroblasts cultured on a 
chamber slide for (c) psoriasin (S100A7, green) and (d) koebnerisin (S100A15, red), nuclei were stained with 
DAPI (blue). Staining represent one of three independent experiments. 
 
An expression in resident dermal and epidermal cells could be demonstrated. Both S100-proteins 
are immune modulators, it is important to analyze whether circulating immune cells express 
psoriasin (S100A7) and/or koebnerisin (S100A15).  
 
In collaboration with Zack Howard from the Laboratory of Molecular Immunoregulation, Cancer and 
Inflammation Program (Center for Cancer Research, Bethesda, Maryland, USA), lymphocytes, 
macrophages and neutrophils were isolated from human blood. All tested immune cell expressed 
psoriasin (S100A7) and koebnerisin (S100A15), but their expression patterns was different. The 
expression of psoriasin (S100A7) was low in monocytes and lymphocytes compared to both splice 
variants of koebnerisin (S100A15L and S100A15S) that showed a stronger expression (Figure 3.2a 
and b). 
The opposite pattern was detected in neutrophils, where psoriasin (S100A7) was stronger expressed 
than both splice variants of koebnerisin (S100A15L and S100A15S) (Figure 3.2c). 
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Figure 3.2: Circulating immune cells express psoriasin (S100A7) and koebnerisin (S100A15). RNA was 
isolated from human lymphocytes, macrophages and neutrophils, transcribed into cDNA and transcript levels 
were analyzed with specific primer for psoriasin (S100A7) and koebnerisin (S100A15L and S100A15S) genes by 
qPCR, β-actin was used as the housekeeping-gene. Data are mean ± SD of 5 patients performed in duplicates 
*, p < 0.05 determined by Student’s t test. 
 
According to the aim 1, data showed the different expressions of psoriasin (S100A7) and koebnerisin 
(S100A15) in circulating immune- as well as non-immune cells. Expressed by epidermal keratinocytes 
and circulating immune cells the expression pattern of psoriasin (S100A7) was different compared to 
koebnerisin (S100A15). Besides keratinocytes, also dermal fibroblasts and circulating immune cells 
expressed koebnerisin (S100A15). Thus, the regulation of both S100-proteins during chronic and 
acute inflammation was investigated next.  
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3.2 Regulation of psoriasin (S100A7) and koebnerisin (S100A15) in skin inflammation 
 
Psoriasis is a chronic auto-inflammatory skin disease that affects about 2-3% of Caucasian people. 
Psoriasis is characterized by disturbed keratinocyte differentiation and dysfunction between 
keratinocytes and the infiltrating inflammatory cells (Lowes et al., 2007; Nickoloff, 2006). The innate 
and adaptive immune system is activated in psoriatic epidermis by an up-regulated expression of 
multifunctional S100-proteins, which in turn further facilitate the inflammatory response because of 
their capability to act as chemoattractants for leukocytes, thus they link innate and adaptive 
immunity. Th1/Th17 differentiated T cells as well as neutrophils, macrophages and dendritic cells are 
responsible for the pathogenesis and typical psoriasis cytokine-milieu (Lowes et al., 2007). In this 
part of the study, I analyzed the role of psoriasin (S100A7) and koebnerisin (S100A15) as possible 
markers for psoriasis susceptibility and manifestation. 
3.2.1 Psoriasin (S100A7) and koebnerisin (S100A15) are up-regulated in non-lesional and lesional 
psoriatic skin 
Psoriasin (S100A7) and koebnerisin (S100A15) are highly homolog in their amino acid sequence but 
have to be distinguished because of their different expression and function. Whereas psoriasin 
(S100A7) is encoded by a single transcript, two transcript variants of koebnerisin, S100A15L (long) 
and S100A15S (short) are described to encode for the same protein (Wolf et al., 2003). Psoriasin 
(S100A7) and koebnerisin (S100A15) are strongly increased in psoriatic lesions, but little is known 
about the expression in non-lesional skin. Up-regulation of both S100-proteins in non-lesional skin 
suggests that psoriasin (S100A7) and/or koebnerisin (S100A15) might serve as markers for disease 
susceptibility. 
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Figure 3.3: S100-proteins are up-regulated in non-lesional and lesional psoriatic skin. RNA was isolated from 
human psoriatic and healthy skin samples, transcribed into cDNA and transcript levels were analyzed with 
specific primer for psoriasin (S100A7) and koebnerisin (S100A15L and S100A15S) genes by qPCR, PBGD was 
used as the housekeeping-gene. Data are mean ± SD of 9 to 12 patients performed in duplicates *, p < 0.05; **, 
p < 0.01; ***, p < 0.001 determined by Student’s t test. 
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The expression level of psoriasin (S100A7) was increased in non-lesional (P-NL) skin and further 
increased in the psoriatic lesions (P-L) (Figure 3.3a). The regulation pattern of the koebnerisin long 
splice variant (S100A15L) was similar to psoriasin (S100A7), but the expression level was generally 
higher (Figure 3.3b). No significant regulation on mRNA level could be measured for the koebnerisin 
short (S100A15S) splice variant, a slight decreased expression in the non-lesional and an increased 
expression in the lesional psoriatic skin could be measured (Figure 3.3c). 
The expression pattern and protein localization of psoriasin (S100A7, green) and koebnerisin 
(S100A15, red) could be determined with an immunofluorescent staining in healthy and psoriatic 
skin. In healthy skin psoriasin (S100A7) was expressed in the differentiated layers of the epidermis, 
whereas koebnerisin (S100A15) was expressed in non-differentiated keratinocytes, thus in the basal 
layer of the epidermis and in the dermis. Compared to the single staining in healthy skin (Figure 3.1), 
the staining intensity was very weak, caused by adjusted microscope settings, to prevent an 
overexposure in lesional psoriatic skin.  
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Figure 3.4: S100-proteins are up-regulated in psoriatic skin. a) Immunofluorescent staining of frozen sections 
of normal and lesional psoriatic back skin stained for psoriasin (S100A7, green) and koebnerisin (S100A15, 
red). Scale bar 50 = µm b) Lysates from normal and psoriatic skin were subjected to immunoblotting by 
incubation with monoclonal anti-hS100A7 (psoriasin) or affinity-purified polyclonal anti-hS100A15 
(koebnerisin) antibody; shown are representative data from four independent patients. (Hegyi et al., 2012). 
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In psoriasis the thickness of the epidermis increases and the expression of both S100-proteins was 
strongly up-regulated in lesional skin. Psoriasin (S100A7) was mainly expressed in differentiated 
keratinocytes, whereas koebnerisin (S100A15) was expressed in the differentiated as well as in non-
differentiated keratinocytes (Figure 3.4a). The Western blot analysis of healthy and psoriatic skin 
lysates showed a clear up-regulation of psoriasin (S100A7) as well as koebnerisin (S100A15) in the 
psoriatic skin compared to healthy control on protein level. Thus, an up-regulated RNA and protein-
level of psoriasin (S100A7) and koebnerisin (S100A15) was shown in psoriatic skin compared to 
healthy controls (Figure 3.4b), thus both S100-proteins serve as markers for the disease. Due to 
being up-regulated in non-lesional psoriatic skin, psoriasin (S100A7) and koebnerisin (S100A15) may 
also act as marker for psoriasis susceptible skin.  
3.2.2 Psoriasin (S100A7) and koebnerisin (S100A15) are differently regulated through Th17 and Th22 
and TNFα cytokines 
As shown before psoriasin (S100A7) and koebnerisin (S100A15) were up-regulated in psoriatic 
epidermis, but little is known which cytokines induce psoriasin (S100A7) and koebnerisin (S100A15) 
in human epidermal keratinocytes. Th17 and Th22 cytokines are up-regulated in psoriasis, thus their 
capacity to induce psoriasin (S100A7) and koebnerisin (S100A15) was analyzed next.  
To understand the differential regulation of psoriasin (S100A7) and koebnerisin (S100A15) in 
epidermal keratinocytes, I analyzed their sequential induction through single Th17 cytokines (Figure 
3.5a–c). All cytokines individually induced psoriasin (S100A7), whereas treatment with IL-17A had a 
maximal effect at 24 hours followed by TNFα and IL-22 with the same pattern, but to a lesser extent. 
Koebnerisin (S100A15) paralleled the psoriasin (S100A7) expression pattern by IL-17A but was 
induced to a higher extend compared with psoriasin (S100A7). TNFα also had a more pronounced 
effect on the long splice variant of koebnerisin (S100A15L) expression by keratinocytes compared to 
psoriasin (S100A7) at 24 hours. However, the short splice variant of koebnerisin (S100A15S) was not 
induced, thus no late but an early peak at 6 hours together could be measured, comparable with the 
long splice variant of koebnerisin (S100A15L). IL-22 alone had little effect on the regulating of 
psoriasin (S100A7) or both koebnerisin isoforms (S100A15L and S) in keratinocytes. The differential 
induction pattern of psoriasin (S100A7) and koebnerisin (S100A15) by individual Th17 cytokines 
could resemble their differential expression pattern in the inflamed psoriatic epidermis. The 
combined Th17 cytokine-milieu in psoriasis may contribute to their co-up-regulation and release by 
psoriatic keratinocytes and allows them to synergize as extracellular chemoattractants.  
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Figure 3.5: Th17/Th22 cytokines differently regulate psoriasin (S1000A7) and koebnerisin (S100A15) in a 
dose- and time-dependent manner. Differential regulation of psoriasin (S100A7) and koebnerisin alternate 
mRNA isoforms (S100A15L, S100A15S) in primary human keratinocytes after treatment with IL-17A, TNFα or IL-
22 at indicated concentrations over time and analyzed by qPCR. Data are mean ± SD of three independent 
experiments performed in triplicate; *P<0.05 determined by Student’s t-test. NC, negative control (Hegyi et al., 
2012). 
 
Combined cytokine treatment was superior over exposure to a single cytokine reflecting the 
pronounced S100 induction in the epidermis by Th17 cytokines that are pathophysiologically 
increased in the psoriatic skin (Figure 3.6a-c). Among the cytokine compositions analyzed, IL-17A 
with TNFα or IL-22 similarly amplified the expression of psoriasin (S100A7) and koebnerisin (long 
S100A15 alternate splice variant (S100A15L)), whereas the alternate spliced short S100A15 variant 
(S100A15S) isoform followed this pattern to a lesser extent. The most pronounced psoriasin 
(S100A7) and koebnerisin (S100A15) induction was observed after combined treatment of 
keratinocytes with IL-17A and TNFα. 
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Figure 3.6: Combined stimulation with Th17/Th22 cytokines induces S100-proteins in human epidermal 
keratinocytes. Primary human keratinocytes were treated with IL-17A (10 ng/ml), IL-22 (10 ng/ml), TNFα (100 
ng/ml) alone or in indicated combinations. Cells were harvested after 24 hours and S100 transcript levels were 
analyzed by qPCR and compared to β-actin using gene specific primer. Data are mean ± SD of a single 
experiment performed in triplicates; *, p < 0.05 determined by Student’s t-test (Hegyi et al., 2012). 
 
These results showed that the single stimulation with IL-17A, IL-22 or TNFα led to a small increased 
induction, whereas the combined stimulation showed the highest up-regulation on the tested S100 
gene expression. Psoriasin (A100A7), koebnerisin long (S100A15L) as well as the short splice variant 
of koebnerisin (S100A15S) showed the biggest inductions in keratinocytes when co-stimulated with 
IL-17A and TNFα. These results could be confirmed on protein level, the strongest release of 
psoriasin (S100A7) and koebnerisin (S100A15) could be measured after the combined stimulation 
with IL-17A and TNFα in Western blot analysis (Hegyi et al., 2012). 
3.2.3 The Th1/Th17 cytokines IFNγ and IL-17A synergize to induce S100 expression in human 
epidermal keratinocytes 
Th1/Th17 cytokines participate in the pathogenesis of auto-inflammatory diseases like rheumatic 
arthritis, Crohn’s disease or psoriasis thus playing important roles during inflammation. As shown 
before, both highly homolog S100-proteins were strong up-regulated in psoriatic skin. To analyze if 
the typical psoriatic Th1/Th17 cytokine-milieu is responsible for the increased S100-protein 
expression human epidermal keratinocytes were stimulated with Th1 and Th17 cytokines alone or in 
combination (Figure 3.7a-c). Stimulation with IFNγ led to a slightly increased expression of psoriasin 
(S100A7) and the long splice variant of koebnerisin (S100A15L), only the short splice variant of 
koebnerisin (S100A15S) did not show any regulation. But the single stimulation with IL-17A 
increased the expression of all tested S100-proteins. However, the combined Th1/Th17 cytokine 
stimulation showed a strongly increased expression of psoriasin (S100A7) and the long splice variant 
of koebnerisin (S100A15L), whereas the short splice variant of koebnerisin (S100A15S) was not 
further induced. 
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Figure 3.7: The mixed Th1/Th17 cytokine-milieu is crucial for up-regulation of S100-proteins in human 
epidermal keratinocytes. Human epidermal keratinocytes were stimulated with IFNγ (100 ng/ml) or IL-17A (10 
ng/ml) alone or in combination for 24 hours. Transcript levels were analyzed with specific primer for psoriasin 
(S100A7) and both koebnerisin splice variants (S100A15L, S100A15S) by qPCR, β-actin was used as the 
housekeeping-gene. Data are mean ± SD of three experiments performed in triplicates; *, p < 0.05; **, p < 
0.01; ***, p < 0.001 determined by ANOVA. 
 
These results showed that psoriasin (S100A7) as well as koebnerisin (S100A15) were strongly 
induced in the mixed Th1/Th17 cytokine-milieu, suggesting to be important as pathogenic factors in 
psoriatic inflammation. 
3.2.4 UVB regulates the S100 gene expression in human epidermal keratinocytes 
The human skin is constantly exposed to UVB irradiation, but the impact to regulation antimicrobial 
peptides in keratinocytes is still not fully understood. In this study the regulation of a time- and 
dose-dependent UVB irradiation on S100-protein expression was analyzed.  
In generally, the short incubation time after UVB did not induce the S100-protein expression, 
independent of the UVB dose. Furthermore, the long splice variant of koebnerisin (S100A15L) was 
stronger induced compared to psoriasin (S100A7) and the lowest induction was measured for the 
short splice variant of koebnerisin (S100A15S). The strongest induced expression of psoriasin 
(S100A7) and both splice variants of koebnerisin (S100A15L and S) could be measured after high-
dose-UVB and long incubation compared to the untreated control (Figure 3.8a-c). However, the 
expression of the psoriasin (S100A7) receptor RAGE was totally different compared to the high 
homolog S100-proteins. RAGE showed an up-regulated RNA level after higher UVB doses and the 
short incubation period post UVB, the longer incubation only showed an induced RNA level after the 
high UVB irradiation dose, lower dose did not show any regulation (Figure 3.8d). 
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Figure 3.8: UVB induce time- and dose-dependent S100-proteins in human epidermal keratinocytes. Human 
epidermal keratinocytes were irradiated with 10, 20 and 30 mJ/cm
2
 UVB and harvested after 3 or 24 hours 
incubation. The expression level of a) psoriasin (S100A7), b) koebnerisin long (S100A15L), c) koebnerisin short 
(S100A15S) and d) RAGE were measured by qPCR compared to β-actin using gene specific primer. Data are 
mean ± SD of three experiments performed in triplicates *, p < 0.05; **, p < 0.01; ***, p < 0.001 determined by 
ANOVA. 
 
Under the same conditions human epidermal keratinocytes were treated on a chamber slides and 
the protein expression of psoriasin (S100A7, green) and koebnerisin (S100A15, red) were analyzed 
by immunofluorescent staining. 
Only a very weak expression of psoriasin (S100A7, green) and koebnerisin (S100A15, red) could be 
detected in the untreated control. Surprisingly already after low-dose UVB a slight increased 
expression of koebnerisin (S100A15) could be measured, whereas the expression of psoriasin 
(S100A7) was nearly the same compared to the untreated control. At the higher dose UVB 
irradiation, no RNA induction could be observed, but the high dose UVB led to a strong increased 
expression of both S100-proteins (Figure 3.9). 
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Figure 3.9: UVB induces time and dose-dependent S100-proteins in human epidermal keratinocytes. 
Human epidermal keratinocytes were seeded on a chamber slide and irradiated with 10, 20 or 30 mJ/cm
2
 or 
leaved untreated as a control. After 48 hours of incubation keratinocytes were immunofluorescent stained 
with specific antibodies for psoriasin (S100A7, green) and koebnerisin (S100A15, red; antibody 3090). Nuclei 
were stained with 40-6-diamidino-2-phenylindole (DAPI; blue). Grey color shows the single staining.  
 
Accordingly to aim 2, these results showed that endogenous factors like the surrounding cytokine-
milieu and exogenous factors like UVB irradiation regulate the highly homolog S100-proteins 
expression in human epidermal keratinocytes. Nevertheless, psoriasin (S100A7) and koebnerisin 
(S100A15) need to be discriminated, their regulation patterns were comparable but not the same. In 
total, the amount of psoriasin (S100A7) induced RNA was much lower compared to the koebnerisin 
(S100A15) expression level. 
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3.3 Function of psoriasin (S100A7) and koebnerisin (S100A15) during inflammation 
Psoriasis is a common auto-inflammatory disease involving the skin in which interleukin-1β (IL-1β) is 
an important mediator for the development of the inflammatory Th17 phenotype (Nestle et al., 
2009b). In particular, the IL-23-mediated differentiation of pathogenetic Th17 cells depends on the 
presence of IL-1β (Ghoreschi et al., 2010). Psoriasis is characterized by inflamed skin caused by an 
up-regulated level of pro-inflammatory mediators. One of the best described and most potent pro-
inflammatory cytokine is IL-1β. Produced as a precursor, pro-IL-1β has to be activated by pro-
inflammatory caspases, like caspase-1 or -5. As well as IL-1β, the caspases are expressed in pro-
forms and have to be proteolytically cleaved by protein complexes called ‘inflammasomes’. The first 
discovered inflammasome was the NALP1 inflammasome and until now it is the only one known to 
bind two different caspases, namely caspase-1 and caspase-5. Other inflammasome complexes, such 
as NALP3 or AIM2, are known to bind just caspase-1. After oligomerization of the complex, the pro-
caspases get activated and in turn cleave the biologic inactive pro-IL-1β. To date, very little is known 
about the regulation of pro-inflammatory cytokines and pro-inflammatory caspases in the skin of 
patients with psoriasis, and further, if S100-proteins are able to regulate the activity of the 
inflammasomes.  
3.3.1 IL-1β, pro-inflammatory caspases and inflammasome complexes are up-regulated in lesional 
psoriatic skin 
A S100-protein up-regulated expression in non-lesional and lesional psoriatic skin, the expression 
levels of IL-1β, pro-inflammatory caspases, NALP1, NALP3 and AIM2 were analyzed by qPCR. 
In chronic inflamed psoriatic skin (P-L) the expression level of IL-1β and both pro-inflammatory 
caspase-1 and caspase-5 were strongly up-regulated compared to healthy controls (NS), whereas IL-
1β showed the strongest increased expression. In the non-lesional-skin (P-NL) the expression of IL-1β 
and both caspases were slightly down-regulated (Figure 3.10a-c). No regulation of NALP1 could be 
measured in the chronic inflamed and non-lesional skin compared to the healthy controls (Figure 
3.10d). However, NALP3 and AIM2 showed a strongly increased expression in lesional psoriatic skin 
compared to the healthy controls, but just a very slight regulation in the non-lesional skin. The 
strongest up-regulated RNA level was detected for AIM2 (Figure 3.10e and f). 
However, caspase-5 as well as its substrate IL-1β were strongly induced in skin of patients with 
psoriasis.  
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Figure 3.10: IL-1β, pro-inflammatory caspases and inflammasomes are up-regulated in lesional psoriatic skin. 
RNA from non-lesional and lesional skin of psoriasis patients was isolated and IL-1β, caspase-1, caspase-5, 
NALP1, NALP3 and AIM2 transcript levels were analyzed by qPCR compared to PBMG using gene specific 
primers. Data are mean ± SD of 9 to 12 patients *, p < 0.05; **, p < 0.01;  determined by Student’s t test. NS= 
normal skin; P-NL= psoriatic non-lesional skin; P-L= psoriatic lesional skin. 
 
To analyze the localization of caspase-5 in the healthy and psoriatic skin, immunofluorescent 
staining of frozen tissue sections was performed. The plaques of patients with psoriasis showed a 
typical morphology, the epidermis is much thicker compared to healthy controls, additionally the 
plaques are colored red and are often covered with scaly keratinocytes, thus, the color seemed to be 
sliver to white. 
 
The immunofluorescent staining of caspase-5 showed that the protease is expressed in the basal 
layer of the epidermis, thus in undifferentiated keratinocytes of healthy skin. No staining could be 
detected in the underlying dermis. In psoriatic skin sections, the prominent staining of caspase-5 
throughout the layers of the psoriatic epidermis reflects the enhanced expression of the NALP1 
inflammasome associated component in psoriasis (Figure 3.11). The expression pattern of this pro-
inflammatory caspase is comparable to the expression of koebnerisin (S100A15) in human skin 
(Figure 3.1). It seemed that the expression per cell in the healthy control was higher compared to 
the psoriatic skin cells, but an increased amount of keratinocytes and the expression in 
differentiated skin layers resulted in an increased amount of caspase-5 in lesional psoriatic skin 
compared to healthy skin. 
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Together, these results showed a strong up-regulation of IL-1β as well as both pro-inflammatory 
caspases and psoriasin (S100A7) and koebnerisin (S100A15) on RNA-level in the full skin probes in 
lesional psoriatic skin. Surprisingly, the regulation in non-lesional psoriatic skin differ totally between 
S100-proteins, pro-inflammatory cytokines and caspases gene expression: whereas psoriasin 
(S100A7) as well as koebnerisin (S100A15) showed a slight up-regulation on RNA level in non-
lesional psoriatic skin, the expression of IL-1β, caspase-1 and caspase-5 showed a down-regulation 
under the same conditions. These results led to the assumption that the S100-proteins may be 
responsible for the regulation of IL-1β, caspase-1 and caspase-5. This was analyzed in the next 
experiments. 
3.3.2 Th1/Th17 cytokines are crucial for the regulation of IL-1β and pro-inflammatory caspases in 
human epidermal keratinocytes 
To identify the factors that regulate the epidermal NALP1 inflammasome in psoriasis, keratinocytes 
were exposed to disease-relevant Th1/Th17 cytokines. Data showed that both Th17-associated 
cytokines TNFα and IL-17A induced pro-IL-1β but had no regulatory effect on NALP1-associated 
caspase-1 or caspase-5 in human keratinocytes (Figure 3.12a-c). In comparison, Th1-associated IFNγ 
 
Figure 3.11: Caspase-5 is up-regulated in psoriatic skin compared to healthy control. Immunofluorescent 
staining of frozen sections of normal and lesional psoriatic skin stained for caspase-5 (red) (Cell Signalling 
1:50), nuclei were stained with DAPI (blue). Bar = 100 µm. Data are shown as examples as one of three 
different patients. 
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strongly induced caspase-1 and caspase-5 besides pro-IL-1β, whereas the expression of the NALP1 
complex remained largely unaffected by either IFNγ or IL-17A treatment. However, TNFα stimulated 
human keratinocytes down-regulated NALP1 (Figure 3.12d).  
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Figure 3.12: Th1/Th17 cytokines differently induce pro-inflammatory cytokines in human epidermal 
keratinocytes. Human epidermal keratinocytes were stimulated with TNFα (50 ng/ml), IFNγ (100 ng/ml) or IL-
17A (10 ng/ml) for 24 hours. Transcript levels were analyzed with specific primers for IL-1β, caspase-1, 
caspase-5 and NALP1 by qPCR, β-actin was used as the housekeeping-gene. Data are mean ± SD of three 
independent experiments performed in triplicates; *, p < 0.05; **, p < 0.01; ***, p < 0.001 determined by 
Student’s t test. 
 
Single stimulation with Th1 or Th17 cytokines only had a small effect on the expression of pro-
inflammatory IL-1β and caspases, but the psoriatic epidermis is exposed to a mixed inflammatory 
milieu, and I hypothesized that Th1/Th17 key cytokines are crucial for the control of the NALP1 
inflammasome activity and IL-1β release by epidermal keratinocytes. Data showed that 
keratinocytes stimulated with either IL-17A or IFNγ up-regulated IL-1β, and the combined treatment 
amplified the IL-1β expression (Figure 3.13a). Keratinocytes treated with IFNγ up-regulated caspase-
1 and caspase-5, whereas treatment with IL-17A did not show any regulation (Figure 3.13b and c). 
Combined stimulation with IFNγ and IL-17A further induced NALP1-associated caspase-1 but 
fortified the expression of caspase-5, which is exclusively utilized by the NALP1 inflammasome. In 
contrast, IL-17A single stimulation had no regulating effect on NALP1 but suppressed the IFNγ-
induced expression of NALP3 and AIM2 that solely activate caspase-1 (Figure 3.13d and f). Data 
suggested that IL-17A shifts the IFNγ-induced inflammasome regulation and IL-1β production by 
epidermal keratinocytes, which was analyzed next. 
Comparing the pro-inflammatory caspases with AIM2 and NALP3, an inverted expression pattern 
could be seen: an increased expression in the combined stimulation of Th1/Th17 cytokines on the 
RNA level of caspase-1 and caspase-5 whereas the same stimulation led to a decreased expression of 
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NALP3 and AIM2. These data showed that the Th1/Th17 cytokine-milieu is crucial for the regulation 
of different pro-inflammatory caspases as well as AIM2 and NALP3. 
 
Together, data indicate that the investigated Th1/Th17 cytokines are important for inflammasome 
regulation in epidermal keratinocytes in a mixed cytokine-milieu (Figure 3.14). The combined 
stimulation of keratinocytes with IFNγ and IL-17A amplified the NALP1-specific caspase-5 more than 
the inflammasome-promiscuous caspase-1 and further down-regulated NALP3 and AIM2 compared 
to NALP1. Thus, IL-17A antagonized the broad inflammasome inducing effect by IFNγ and 
suppressed the IL-1β activation by epidermal keratinocytes when exposed to the mixed Th1/Th17 
cytokine-milieu, which is an important therapeutic target in psoriasis and other Th17-mediated auto-
inflammatory skin diseases.  
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Figure 3.13: The cytokine-milieu is crucial for up-regulation of pro-inflammatory cytokines and the down-
regulation of the inflammasome complexes. Human epidermal keratinocytes were stimulated with IFNγ (100 
ng/ml) and/or IL-17A (10 ng/ml) for 24 hours. Transcript levels were analyzed with specific primers for IL-1β, 
caspase-1, caspase-5, NALP1, NALP3 and AIM2 by qPCR, β-actin was used as the housekeeping-gene. Data are 
mean ± SD of three experiments performed in triplicates; *, p < 0.05; **, p < 0.01; ***, p < 0.001 determined 
by ANOVA. 
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3.3.3 Psoriasin (S100A7) is a key regulator of IL-1β and pro-inflammatory caspases under the 
Th1/Th17 cytokine-milieu 
Psoriasin (S100A7) and koebnerisin (S100A15) were discovered up-regulated in epidermal 
keratinocytes of psoriatic skin and synergize as chemoattractants for leukocytes important for the 
inflammatory phenotype in psoriasis (Madsen et al., 1991; Wolf et al., 2008; Wolf et al., 2003). As 
danger-associated molecular patterns (DAMPs), both S100-proteins are induced by disease-relevant 
Th1/Th17 cytokines in the psoriatic epidermis and released by epidermal keratinocytes (Wolf et al., 
2010a). The capacity of psoriasin (S100A7) to regulate the NALP1 inflammasome and its components 
was analyzed next. 
To further investigate the impact of psoriasin (S100A7) on inflammasome regulation, cultured 
human epidermal keratinocytes were stimulated with IFNγ. Co-transfection with siRNA targeting 
psoriasin (S100A7) suppressed the expression of pro-inflammatory caspase-1 and caspase-5 
compared to pro-IL-1β, which was induced (Figure 3.15a).  
Stimulation with IFNγ and IL-17A further induced the psoriasin (S100A7) expression in human 
keratinocytes, the combined treatment of Th1/Th17 cytokines as well as silencing psoriasin (S100A7) 
had an amplifying effect on the caspase-1 and caspase-5 expression. However, the combined 
 
Figure 3.14: Inflammasome regulation by the Th1/Th17 micro-milieu in human epidermal keratinocytes. 
The pro-inflammatory micro-environment in psoriatic skin lesions contains IFNγ and IL-17A, which induce 
NALP1-specific caspases-5 more than inflammasome-promiscuous caspase-1 in keratinocytes. IFNγ and IL-17A 
further down-regulated NALP3 and AIM2 compared to NALP1. Thus, IL-17A antagonizes the broad 
inflammasome-inducing effect mediated by IFNγ and results in a reduced IL-1β release by epidermal 
keratinocytes. 
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stimulation with IFNγ, IL-17A and psoriasin (S100A7) siRNA had no regulatory effect of IL-1β (Figure 
3.15b).  
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Figure 3.15: Psoriasin (S100A7) has a different effect on the regulation of IL-1β and pro-inflammatory 
caspases, dependent on the surrounding cytokine-milieu. a) Human epidermal keratinocytes were 
transfected with psoriasin (S100A7) siRNA for 48 hours and then stimulated with IFNγ (100 ng/ml) or b) 
combined with IL-17A (10 ng/ml) for 24 hours. Transcript levels were analyzed with specific primers for IL-1β, 
caspase-1 and caspase-5 by qPCR, β-actin was used as the housekeeping-gene. Data are mean ± SD of three 
experiments performed in triplicates; *, p < 0.05; **, p < 0.01; ***, p < 0.001 determined by student’s t-test. 
 
Like IL-1β also NALP1 and NALP3 were up-regulated after IFNγ stimulation and by psoriasin silencing 
(S100A7-siRNA) by siRNA, whereas AIM2 was down-regulated. The co-stimulation with IFNγ and IL-
17A reduced the expression of all tested inflammasomes, NALP3 and AIM2 were strongly down-
regulated. Thus the regulation of NALP3 was IL-17A depended (Figure 3.16a and b). 
 
Data indicate that the IFNγ-induced expression of pro-inflammatory caspases and inflammasomes 
are mediated by psoriasin (S100A7). Additional stimulation with IL-17A increased the regulation of 
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Fig. 3.16: Psoriasin (S100A7) has a crucial effect on the regulation of inflammasome complexes dependent on 
the surrounding cytokine-milieu. a) Human epidermal keratinocytes were transfected with psoriasin (S100A7) 
siRNA for 48 hours and then stimulated with IFNγ (100 ng/ml) or b) combined with IL-17A (10 ng/ml) for 24 
hours. Transcript levels were analyzed with specific primers for NALP1, NALP3 and AIM2 by qPCR, β-actin was 
used as the housekeeping-gene. Data are mean ± SD of three experiments performed in triplicates; *, p < 0.05; 
**, p < 0.01; ***, p < 0.001 determined by student’s t-test. 
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both caspases and AIM2, thus a strong regulatory effect of psoriasin (S100A7) was detected. 
However, expression of IL-1β and NALP1 were rescued after additional stimulation with IL-17A. The 
fortified expression of psoriasin (S100A7) under Th1/Th17 cytokines might further enhance the 
effect on NALP1 inflammasome regulation. 
3.3.4 Psoriasin (S100A7) and koebnerisin (S100A15) synergize as ‘alarmins’ to regulate pro-
inflammatory cytokines and other antimicrobial peptides in epidermal keratinocytes 
To investigate the role of psoriasin (S100A7) and koebnerisin (S100A15) during inflammation, human 
epidermal keratinocytes were treated with both S100-proteins alone or in combination and their 
regulation capacity of pro-inflammatory cytokines as well as further anti-microbial peptides was 
measured.  
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Figure. 3.17: The ‘alarmins’ psoriasin (S100A7) and koebnerisin (S100A15) synergize to regulate pro-
inflammatory cytokines and antimicrobial peptides in epidermal keratinocytes. Primary human keratinocytes 
were treated with psoriasin (S100A7, 100 ng/ml) and koebnerisin (S100A15, 100 ng/ml) alone or in 
combination and expression of indicated pro-inflammatory mediators and antimicrobial peptides was analyzed 
by qPCR after 1 hour. Data are mean ± SEM of three independent experiments performed in triplicate; *p<0.05 
determined by Student’s t-test (Hegyi et al., 2012). 
 
The pro-inflammatory cytokines TNFα, IL-6 and IL-8 were significantly up-regulated after the 
combined stimulation with psoriasin (S100A7) and koebnerisin (S100A15). IL-6 showed an up-
regulated RNA level after the single stimulation with koebnerisin (S100A15), whereas no further 
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increased expression could be measured in single stimulation with neither psoriasin (S100A7) nor 
koebnerisin (S100A15) (Figure 3.17a-c). Independently from single or combined stimulation with 
psoriasin (S100A7) and/or koebnerisin (S100A15) any regulation of S100A8 and the antimicrobial 
peptide RNase7 could be detected (Figure 3.17d-f). Whereas hDB2 (human beta defensin 2), another 
AMP, showed a decreased expressions after the single stimulation with psoriasin (S100A7) and 
koebnerisin (S100A15), the combined stimulation reduced the expression compared to the 
untreated control (Figure 3.17e). 
These results confirmed the hypothesis that psoriasin (S100A7) and koebnerisin (S100A15), like 
other S100-proteins, belong to the group of ‘alarmins’. 
3.3.5 IFNγ and double stranded DNA are required to activate inflammasomes in human epidermal 
keratinocytes 
IL-1β is expressed as a precursor and needs to be activated by proteolytic cleavage. After activation 
of the inflammasome complex pro-inflammatory caspases get activated by binding to the complex. 
Only cleaved caspases are able to process pro-IL-1β into the active IL-1β. 
Data identified IFNγ as a major regulating factor for both NALP1 inflammasome associated caspases 
but keratinocytes stimulated with IFNγ alone did not release mature IL-1β into the culture 
supernatant (Figure 3.18).  
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Figure 3.18: Stimulation with double stranded DNA is required to activate inflammasome complexes and IL-
1β release. Human epidermal keratinocytes were stimulated with IFNγ (100 ng/ml) and transfected with 
double strand DNA (1 µg/ml) or DNase digested DNA. After 24 hours incubation cells-lysats and supernatants 
were harvested and the mature released IL-1β concentration in the supernatant was analyzed by ELISA. Data 
are mean ± SD of three independent experiments performed in duplicates; ***, p < 0.001 determined by 
ANOVA, n.d. indicates not detectable. 
Free cytosolic double-stranded (ds)DNA [Poly(dA:dT)] fragments are detectable in epidermal 
keratinocytes from psoriatic patients (Dombrowski et al., 2011), and I proved the hypothesis that 
dsDNA activates the NALP1 inflammasome complex and leads to IL-1β activation and release. 
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Whereas transfected primary keratinocytes with dsDNA alone did not affect the IL-1β activation, 
priming of keratinocytes with IFNγ with additional transfection with dsDNA induced the activation 
and release of mature IL-1β into the culture supernatant. Simultaneous DNase treated dsDNA 
decreased the IL-1β release and confirmed that cytosolic dsDNA is required for inflammasome 
activation (Figure 3.18). Neither stimulation with cytokines nor with transfected dsDNA induced 
apoptosis, tested with the crystal-violet assay. 
To show the activity of NALP1-associated caspases, human keratinocytes were primed with IFNγ, 
transfected with dsDNA and the cell culture lysates and supernatants were analyzed by Western 
blots (Figure 3.19).  
 
In the lysates of IFNγ treated keratinocytes, pro-caspase-1 and pro-caspase-5 were detected, 
whereas transfection with dsDNA or DNase digested DNA did not influence on the expression of 
both pro-caspases. Cleaved caspase-1 could be detected in every stimulation conditions but the 
highest amount was measured in the DNase digested DNA probe. Active caspase-5 was hardly 
detectable but a very light band could be detected in the DNase digested DNA probe (Figure 3.19, 
 
Figure 3.19: Stimulation with double stranded DNA is required to activate caspase-1. Human epidermal 
keratinocytes were stimulated with IFNγ (100 ng/ml) and transfected with double strand DNA (1 µg/ml) or 
DNase treated DNA and transfected afterwards. After 24 hours incubation cell-lysates and supernatants were 
harvested and caspase-1 (1:1000) as well as caspase-5 (1:500) in the lysates and supernatants were analyzed 
by Western blot analysis. α-tubulin was used as a house keeping protein for the lysates, a Ponceau staining 
was used as loading control for the supernatant samples.  
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left panel). Keratinocytes treated with IFNγ expressed pro-caspase-1 (control), while transfection 
with dsDNA induced caspase-1 cleavage (-DNase) that vanished in DNase treated samples (+DNase). 
Analysis of corresponding samples for caspase-5 showed a similar pattern but the bands were less 
prominent (pro-caspase-5) and barely detectable (cleaved caspase-5) in the keratinocyte 
supernatants (Figure 3.19, right panel). 
Taken together, these results showed that priming and activation of the inflammasome is necessary 
to release mature IL-1β in the supernatants of epidermal keratinocytes. Priming the inflammasome 
is possible with IFNγ and an activator of the inflammasome complex in epidermal keratinocytes is 
cytosolic dsDNA. The pro-inflammatory caspases were detectable in the lysates but differently 
regulated. In the precipitated supernatants, exclusively the active caspase-1 could be detected in 
IFNγ and dsDNA treated keratinocytes, whereas active caspase-5 was not detectable.  
3.3.6 Th17 cytokine IL-17A suppresses IFNγ induced release of IL-1β by human epidermal 
keratinocytes 
Data shown before indicated, that different cytokine-milieus are crucial for the gene regulation of IL-
1β and pro-inflammatory caspases as well as different inflammasomes. To investigate the role IL-17A 
on the inflammasome priming or activation, human epidermal keratinocytes were stimulated with 
IFNγ, TNFα, IL-17A and transfected with dsDNA. This stimulation was used as a full activated 
inflammasome and used to normalize all further stimulations.  
Priming and activation of the inflammasome complex are needed to receive released mature IL-1β. 
As seen before, stimulation with TNFα increased the pro-IL-1β RNA level, whereas both caspases 
were increased after stimulation with IFNγ. Further transfection with dsDNA activated the 
inflammasome by building the complex. 
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A fully activated inflammasome, thus the full release of mature IL-1β, could be measured after the 
combined priming with TNFα and IFNγ and activating the inflammasome by dsDNA transfection. The 
release of mature IL-1β into the supernatant was reduced without TNFα stimulation. IL-17A alone 
was not able to prime the inflammasome, and activation of the complex with dsDNA alone did not 
release mature IL-1β. Human epidermal keratinocytes transfected with dsDNA and stimulated with 
IFNinduced an IL-1β release, but less compared to the combined priming with TNFα and IFNγ. 
However, combined treatment of keratinocytes with IFNγ and IL-17A suppressed the release of 
mature IL-1β below levels of treatment with IFNγ alone or in combination with TNFα (Figure 3.20).  
These data indicated that IL-17A has a suppressive effect on the IL-1β release after stimulation with 
IFNγ on a dsDNA dependent inflammasome activating manner.  
3.3.7 S100-proteins induce IL-1β release  
To analyze if the S100-proteins regulate the NALP1 inflammasome activity and IL-1β release, human 
epidermal keratinocytes were treated with IFN and transfected with dsDNA, an induced release of 
mature IL-1β into the culture supernatant was detected (Figure 3.21). Co-treatment with psoriasin 
(S100A7) led to an increased IL-1β production that was comparable to co-stimulation with TNFα. In 
contrast, co-treatment of keratinocytes with koebnerisin (S100A15) had no additional IL-1β priming 
effect and was comparable to stimulation of keratinocytes with IFN.  
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Figure 3.21: Psoriasin (S100A7) and koebnerisin (S100A15) have different effects for inflammasome priming 
and activation. Human epidermal keratinocytes were stimulated with IFNγ (100 ng/ml), TNFα (50 ng/ml), 
psoriasin (S100A7, 100 ng/ml) or koebnerisin (S100A15, 100 ng/ml) and transfected with ds DNA (1 µg/ml). 
After 24 hours cells and supernatants were harvested and the mature IL-1β concentrations in the 
Figure 3.20: Th17 cytokine IL-17A decreased the release of mature IL-1β by human epidermal keratinocytes. 
Human epidermal keratinocytes were stimulated with IFNγ (100 ng/ml), TNFα (50 ng/ml) and/or IL-17A (10 
ng/ml) and transfected with double stranded DNA (1 µg/ml). After 24 hours incubation cells and supernatants 
were harvested and the mature released IL-1β concentrations in the supernatants were analyzed by ELISA. 
Data are mean ± SD of a three experiments performed in duplicates; **, p < 0.01; ***, p < 0.001 determined 
by ANOVA. 
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supernatants were analyzed by ELISA. Data are mean ± SD of three experiments performed in duplicates; **, 
p < 0.01; ***, p < 0.001 determined by ANOVA.  
 
Results underline previous findings that the highly homologous psoriasin (S100A7) and koebnerisin 
(S100A15) are functionally distinct (Wolf et al., 2008). 
3.3.8 Cytokine-milieu regulates the inflammasome dependent IL-1β release  
It is still unknown which role each single component of the inflammasome plays and how important 
the cytokine-milieu is to activate the inflammasomes. Data indicate that IFNγ-induced NALP1 
inflammasome components are mediated by psoriasin (S100A7) and the functional relevance of the 
S100-protein for NALP1-dependent IL-1β production was investigated next.  
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Figure 3.22: IFNy and IL-17A regulate NALP1 and IL-1β release in epithelial keratinocytes via psoriasin 
(S100A7). IL-1β release in the supernatant of human epidermal keratinocytes transfected with dsDNA (1 
µg/ml), stimulated with IFNγ (100 ng/ml), and psoriasin (S100A7, 100 ng/ml) and co-treated with siRNA 
targeting caspase-1, caspase-5, NALP1 and non-coding siRNA was analyzed by ELISA. Data are mean ± SD of 
three independent experiments performed in duplicates *, p < 0.05; **, p < 0.01 determined by Student’s t 
test. 
 
Human epidermal keratinocytes stimulated with IFN and transfected with dsDNA released less IL-1β 
when co-transfected with siRNA targeting caspase-1, caspase-5 or NALP1 (Figure 3.22, left panel). 
Co-treatment with psoriasin countervailed the abated expression of caspase-1, caspase-5 and NALP1 
and increased the IL-1β release by human keratinocytes under either conditions (Figure 3.22, right 
panel). 
Taken together these results showed that psoriasin (S100A7) had a pro-inflammatory effect on the 
release of IL-1β into the supernatant dependent on the surrounding cytokine-milieu. 
 
To further investigate the role of the NALP1 inflammasome in the mixed cytokine setting, human 
keratinocytes were transfected with dsDNA additionally stimulated with IFN and IL-17A, and the IL-
1β release was measured dependent on NALP1 inflammasome expression. Co-transfection with 
siRNA either targeting caspases-1 or caspase-5 suppressed the IL-1β release by keratinocytes. The 
Results 
 
 - 67 - 
observed IL-1β reducing effect was comparable to when silencing the NALP1 complex compared to 
targeting the NALP3 complex that did not show a strong decreased IL-1β release compared to the 
non-coding siRNA control (Figure 3.23).  
 
Results indicated that IL-17A antagonized the broad inflammasome-inducing effect by IFNγ and 
suppresses the IL-1β activation by epidermal keratinocytes when exposed to the mixed Th1/Th17 
cytokine-milieu, which is an important therapeutic target in psoriasis and other Th17-mediated auto-
inflammatory skin diseases. 
3.3.9 Role of psoriasin (S100A7) and koebnerisin (S100A15) during UVB-induced acute inflammation 
S100-proteins were shown up-regulated in human epidermal keratinocytes after UVB irradiation. It 
is poorly described which inflammasomes, beside NALP3, are involved after UVB activation and if 
other factors like S100-proteins are involved in acute induced inflammation. 
To investigate which influence UVB alone and combined with S100-proteins had on human 
epidermal keratinocytes, cells were treated and the mature IL-1β was measured. As shown 
previously, IFNγ induces pro-inflammatory caspases, and is needed to prime the inflammasome 
complexes, but the single stimulation was not efficient for an IL-1β release. Single irradiation 
resulted in a slight release of IL-1β that increased after the combined stimulation with IFNγ and UVB. 
Neither stimulation with psoriasin (S100A7) nor with koebnerisin (S100A15) showed a regulated 
released IL-1β level (Figure 3.24). Compared to the cytokine induced inflammation, it seemed that 
psoriasin (S100A7) and koebnerisin (S100A15) did not have a regulatory function during UVB-
induced inflammation. 
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Figure 3.23: IL-17A supports NALP1 inflammasome activity but suppresses the IL-1β production by 
epidermal keratinocytes. IL-1β release in the supernatant of human epidermal keratinocytes transfected with 
dsDNA (1 µg/ml), stimulated with IFNγ (100 ng/ml), IL-17A (10 ng/ml), and co-treated with siRNA targeting 
caspase-1, caspase-5, NALP1, NALP3 and non-coding siRNA was analyzed by ELISA. Data are mean ± SD of 
three independent experiments performed in duplicates ***, p < 0.001 determined by ANOVA. 
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Figure 3.24: Additional stimulation with psoriasin (S100A7) and koebnerisin (S100A15) had no influence on 
UVB-induced IL-1β release. Human epidermal keratinocytes were stimulated with IFNγ (100 ng/ml), psoriasin 
(S100A7), koebnerisin (S100A15) and or irradiated with 30 mJ/cm
2
. After 24 hours cell-lysates and 
supernatants were harvested and the mature released IL-1β concentration in the supernatant was analyzed 
by ELISA. Data are mean ± SD of five independent experiments performed in duplicates; ***, p < 0.001 
determined by ANOVA. 
 
To analyze which inflammasome component is responsible for the IL-1β release human epidermal 
keratinocytes were primed with IFNγ and the inflammasome activated with UVB, further caspase-1, 
caspase-5, NALP1, psoriasin (S100A7) and koebnerisin (S100A15) were silenced by specific siRNA and 
the released IL-1β in the supernatants were analyzed and compared to the non-coding siRNA 
control.  
The strongest decreased IL-1β release was measured after silencing caspase-1. Treatment with 
caspase-5, NALP1 or psoriasin (S100A7) siRNA did not show a regulation on the released IL-1β level 
compared to the non-coding siRNA control. Surprisingly, silencing koebnerisin (S100A15) resulted in 
an increased amount of mature IL-1β, indicating an anti-inflammatory effect of this S100-protein 
(Figure 3.25).  
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Figure 3.25: Release of IL-1β after silencing inflammasome components is caspase-5 independent. Mature 
released IL-1β in the supernatant analyzed by ELISA of human epidermal keratinocytes stimulated with IFNγ 
(100 ng/ml), 10 mJ/cm
2
 and co-treated with specific caspase-1, caspase-5, NALP1, psoriasin (S100A7) and 
koebnerisin (S100A15) siRNA compared to non-coding siRNA. Data are mean ± SD of three independent 
experiments performed in duplicates *, p < 0.05; determined by Student’s t test. 
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According to aim 3, these results showed that the components of the inflammasome as well as S100-
proteins act differently in acute induced inflammation via UVB irradiation compared to the Th1/Th17 
induced chronic inflammation. Two new functions of psoriasin (S100A7) and koebnerisin (S100A15) 
could be described; both S100-proteins synergize as ‘alarmins’ the expression of pro-inflammatory 
cytokines. On the other hand, psoriasin (S100A7) was identified as a multifunctional protein that 
induce IL-1β release through inflammasome regulation in a defined Th1/Th17 cytokine-milieu. The 
regulation capacity of koebnerisin (S100A15) to induce IL-1β in a Th17-mediated cytokine milieu 
could not be shown, whereas in the acute induced inflammation by UVB it seemed that koebnerisin 
(S100A15) had an anti-inflammatory effect. Data demonstrate the need to discriminate the 
surrounding milieu and both highly homolog S100-proteins.  
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3.4 Function of vitamin D in chronic inflamed psoriatic skin 
 
Vitamin D analogs are commonly used as topical therapeutics for psoriasis, but their anti-
inflammatory mechanisms have not yet been fully understood (Fogh and Kragballe, 1997). Vitamin D 
and its analogs strongly affect the differentiation of keratinocytes by binding to the vitamin D 
receptor (VDR) and inducing the expression of genes that are important in keratinocyte 
differentiation. The following data show a new anti-inflammatory mechanism of vitamin D through 
S100-proteins. Additionally, IL-17A was identified as the main inducer of psoriasin (S100A7) and 
koebnerisin (S100A15) in human epidermal keratinocytes and a new function of the induced S100-
proteins as ‘alarmins’ could be described. 
3.4.1 T cell supernatants from patients with psoriasis increase S100 expression in keratinocytes 
To investigate if cytokines expressed by T cells were responsible for the up-regulation of psoriasin 
(S100A7) and koebnerisin (S100A15) in psoriatic skin, keratinocytes (HaCaT) were stimulated with 
the supernatants of isolated T cells from patients with psoriasis (isolation was performed in 
cooperation with the working group of Prof. Dr. Prinz, LMU München).  
 
Psoriasin (S100A7) and both koebnerisin splice variants (S100A15L and S100A15S) showed an 
increased gene expression after stimulation with the supernatants of dermal T cells. These T cells 
were isolated from plaques of patients with psoriasis and cultivated for several days (Figure 3.26). 
The T cell supernatants induced psoriasin (S100A7) and both alternate koebnerisin transcripts 
(S100A15L and S100A15S) in keratinocytes to a similar extent. 
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Figure 3.26: T cell supernatants of psoriasis patients induce S100 transcript level in HaCaT cells. Human 
keratinocytes (HaCaT) were treated with supernatants from T cells isolated from psoriatic plaques. Cells were 
harvested after 24 hours and S100 transcript levels were analyzed by qPCR compared to β-actin using gene 
specific primer. Data are mean ± SD of three independent experiment performed in triplicates *, p < 0.05 
determined by Student’s t-test (Hegyi et al., 2012). 
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3.4.2 IL-17A but not TNFα is the main inducer of S100-‘alarmins’ in psoriasis 
To verify the major role of IL-17A for the epidermal S100-protein regulation in psoriasis, 
keratinocytes were treated with supernatants of cultured dermal T cells isolated from lesional 
psoriatic skin in the presence of IL-17A receptor (IL-17AR) blocking antibodies (Figure 3.27a). The up-
regulation of psoriasin (S100A7) through the T cell supernatant was markedly attenuated by IL-17AR 
blocking antibodies and completely blocked both alternate koebnerisin transcripts (S100A15L and 
S100A15S). However, adding equal amounts of TNFα neutralizing antibody (Ab) to the supernatants 
of cultured psoriatic dermal T cells had only a minor blocking effect on expression of either S100-
protein in keratinocytes (Figure 3.27b). 
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Figure 3.27 IL-17A is the main inducer of psoriasin (S100A7) and koebnerisin (S100A15) in human 
keratinocytes. Human keratinocyte-derived HaCaT cells were treated with supernatants from T cells isolated 
from psoriatic plaques in the presence of (a) IL-17AR neutralizing antibody or (b) TNFα neutralizing Ab 
(golimumab, Simponi) compared with non-immune IgG. Cells were harvested after 24h and S100 transcript 
levels were analyzed by qPCR. Data are mean ± SEM of three independent experiments from individual patients 
performed in triplicate; *p<0.05 determined by Student’s t-test (Hegyi et al., 2012). 
 
To confirm these results, human epidermal keratinocytes were treated with IL-17A and/or 
additionally the IL-17A receptor was blocked by specifically blocking IL-17AR antibodies. Similarly, 
induction of both S100-proteins was neutralized by blocking the IL-17A receptor while keratinocytes 
were stimulated with IL-17A alone (Figure 3.28). 
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Figure 3.28: IL-17A induces S100-‘alarmins’ in human epidermal keratinocytes. Primary human keratinocytes 
were treated with IL-17A (10 ng/ml) in the presence of IL-17AR blocking Ab compared with non-immune IgG. 
Cells were harvested after 24 hours and S100 transcript levels were analyzed by qPCR. Data are mean ± SEM 
of three independent experiments from individual patients performed in triplicate; *p<0.05 determined by 
Student’s t-test (Hegyi et al., 2012). 
 
Further, Hegyi et al. showed an immunofluorescent staining of frozen sections that showed a slight 
staining of IL-17A in the basal layer of the epidermis. Compared to the healthy control, a strong 
increased staining of IL-17A could be observed in psoriatic skin. Mainly in the basal layer, but also in 
the more differentiated keratinocytes and in the dermis the staining could be detected, suggesting 
that in normal and in psoriatic skin, IL-17A regulates psoriasin (S100A7) and koebnerisin (S100A15) 
gene expression. 
Together these results showed that T cell derived IL-17A is the main inducer of psoriasin (S100A7) 
and koebnerisin (S100A15L and S100A15S) in human epidermal keratinocytes. This suggests that 
baseline levels of IL-17A in normal volunteers (Mei et al., 2011; Tanasescu et al., 2010) and increased 
IL-17A levels in psoriasis regulate the differential psoriasin (S100A7) and koebnerisin (S100A15) 
expression in both normal tissue and Th17-mediated diseases. 
3.4.3 1.25-Dihydroxyvitamin D3 (1.25D3) inhibits the Th17-induced expression of psoriasin (S100A7) 
and koebnerisin (S100A15) and suppresses the S100-mediated pro-inflammatory loop in psoriasis  
It is known that calcipotriol, a vitamin D analog, acts anti-psoriatically but the mechanism is not fully 
understood. To investigate the regulation of vitamin D3 in Th17 cytokine-milieu, human epidermal 
keratinocytes were stimulated with IL-17A and additionally treated with 1.25-Dihydroxyvitamin D3 
(1.25D3).  
Results before showed that IL-17A induced the expression of psoriasin (S100A7) and koebnerisin 
(S100A15), after additional treatment with 1.25-Dihydroxyvitamin D3 (1.25D3) the RNA levels of 
psoriasin (S100A7) and both isoforms of koebnerisin (S100A15L and S100A15S) showed a significant 
down-regulation (Figure 3.29).  
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Data shown before indicated that the combination of Th1/Th17 cytokines had a stronger regulatory 
effect on the RNA level of S100-proteins compared to the single stimulation (Figure 3.7), so the 
effect of vitamin 1.25D3 on a mixed cytokine-milieu was analyzed. 
 
Mimicking a Th17/Th22 milieu, keratinocytes were stimulated with a combination of IL-17A and IL-
22 that were able to amplify both psoriasin (S100A7) and koebnerisin (S100A15L and S100A15S) 
transcripts. The increased expression of both S100-proteins in keratinocytes was attenuated in the 
presence of vitamin 1.25D3 with a pronounced effect on the psoriasin (S100A7) and the long splice 
variant of koebnerisin (S100A15L) compared with the short splice variant of koebnerisin (S100A15S) 
(Figure 3.30). 
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Figure 3.29: Vitamin D3 blocks the IL-17A induced expression of S100-‘alarmins’. Primary human 
keratinocytes were treated with IL-17A (10 ng/ ml) in the presence of vitamin 1.25 D3 (10
-9
 M) or vehicle 
control. Expression of psoriasin (S100A7) and koebnerisin (S100A15) alternate mRNA isoforms were analyzed 
by quantitative real-time reverse transcription-PCR analysis. Data are mean ± SEM of three independent 
experiments performed in triplicate; *p<0.05 determined by Student’s t-test. (published: (Hegyi et al., 2012)) 
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Figure 3.30: 1.25-Dihydroxyvitamin D3 (1.25D3) inhibits the Th17-induced expression of psoriasin (S100A7) 
and koebnerisin (S100A15). Primary human keratinocytes were treated with IL-17A (10 ng/ml) in combination 
with IL-22 (10 ng/ml) or TNFα (100 ng/ml) in the presence of vitamin 1.25 D3 (10
-9
 M) or vehicle control. 
Expression of psoriasin (S100A7) and koebnerisin (S100A15) alternate mRNA isoforms was analyzed by 
quantitative real-time reverse transcription-PCR analysis. Data are mean ± SEM of three independent 
experiments performed in triplicate; *p<0.05 determined by Student’s t-test (Hegyi et al., 2012). 
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These results indicated that the combined stimulation of different Th17 cytokines had an impact on 
the amount of induced S100-RNA, whereas the different cytokine stimulation resulted in a different 
regulation pattern of psoriasin (S100A7) and koebnerisin (S100A15L). The effect of 1.25-
Dihydroxyvitamin D3 (1.25D3) resulted in a significant decreased expression of S100-proteins in all 
cytokine stimulations.  
3.4.4 Vitamin D3 analog calcipotriol inhibits the expression of psoriasin (S100A7) and koebnerisin 
(S100A15) in situ 
Because of the synergistic role of psoriasin (S100A7) and koebnerisin (S100A15) as chemoattractants 
(Wolf et al., 2008) and ‘alarmins’ (Figure 3.16) in the pathogenesis of psoriasis, their regulation in 
psoriatic plaques after topical treatment with anti-psoriatic calcipotriol was assessed. Skin sections 
of psoriatic plaques showed a reduced epidermal thickening and further a decreased psoriasin 
(S100A7) and koebnerisin (S100A15) production after calcipotriol treatment (Figure 3.31a).  
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Figure 3.31: Calcipotriol suppresses the expression of the S100-proteins in skin of patients with psoriasis. a) 
Immunofluorescent staining of frozen sections of psoriatic skin before and after treatment with calcipotriol for 
psoriasin (S100A7, green) and koebnerisin (S100A15, red). Nuclei were stained with 40-6-diamidino-2-
phenylindole (DAPI; blue). Bar = 100 µm. b) Lysates from normal and psoriatic skin were subjected to 
immunoblotting by incubation with monoclonal anti-hS100A7 (psoriasin) or affinity-purified polyclonal anti-
hS100A15 (koebnerisin) antibody; shown are representative data from four independent patients. (Hegyi et 
al., 2012). 
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S100-immunoblot analysis from skin biopsies demonstrated the increased production of psoriasin 
(S100A7) and koebnerisin (S100A15) in psoriasis, which was suppressed after treatment of psoriatic 
plaques with calcipotriol (Figure 3.31b). 
 
 
According to aim 4, data suggest that the increased S100-protein production by epidermal 
keratinocytes in a complex Th17 milieu is only slightly affected by direct vitamin D action on 
keratinocytes. However, vitamin D analogs inhibit infiltrating immune cells that create the S100-
inducing Th17 milieu in psoriasis and could explain the marked suppression of the psoriasin (S100A7) 
and koebnerisin (S100A15) expression in psoriatic plaques after calcipotriol treatment (Figure 3.30) 
(Ikeda et al., 2010; van der Vleuten et al., 1996). Thus, vitamin D analogs are able to interfere with 
the inflammatory feedback loop in psoriatic skin by suppressing the Th17-induced pro-inflammatory 
functions of psoriasin (S100A7) and koebnerisin (S100A15) as chemoattractants and ‘alarmins’ 
(Figure 3.32). 
 
 
Figure 3.32: Schematic figure of the vitamin D effect on psoriatic skin. Pro-psoriatic T cell–derived Th17 
cytokines, mainly IL-17A, induce the expression of psoriasin (S100A7) and koebnerisin (S100A15) in epidermal 
keratinocytes. Their increased release from keratinocytes allows them to synergize as extracellular 
chemoattractants for leukocytes and ‘alarmins’ on resident skin cells and thus amplify the inflammatory 
response in psoriasis. Vitamin D analogs suppress the increased production of psoriasin (S100A7) and 
koebnerisin (S100A15) and thus interfere with the S100-mediated pro-inflammatory feedback loop in 
psoriasis (Hegyi et al., 2012). 
 
 - 76 - 
 
 
 
Discussion 
 
 - 77 - 
4. Discussion 
 
4.1 Psoriasin (S100A7) and koebnerisin (S100A15) in skin homeostasis 
The skin is divided into subcutis, dermis and epidermis, each layer having particular functions. The 
subcutaneous layer serves as an isolation and the dermis provides the epidermis with nutrients 
because no blood vessels are located in the outer skin layer. The much thinner epidermis is 
subdivided into four layers and again each with special functions (Steusloff et al., 2000). In healthy 
skin, the epidermal maturation takes about two to four weeks and includes cell proliferation, 
migration and terminal differentiation of epidermal keratinocytes (Fuchs and Byrne, 1994). 
Expressed in healthy skin psoriasin (S100A7) and koebnerisin (S100A15) seem to be important 
during skin homeostasis and keratinocyte differentiation. Both S100-proteins are substrates of the 
transglutaminase I (TGaseI) and are part of the cornified envelope which acts as a physical 
protection of the skin (Steinert et al., 1996). Beside their proposed protective function in the 
cornified envelope, psoriasin (S100A7) and koebnerisin (S100A15) further act as antimicrobial 
peptides and chemoattractants for leukocytes and neutrophils (Eckert et al., 2004; Heizmann et al., 
2002). In healthy skin with a normal epidermal differentiation, psoriasin (S100A7) and koebnerisin 
(S100A7) show a distinct expression. Whereas psoriasin (S100A7) is mainly expressed in 
differentiated layers of the epidermis, koebnerisin (S100A15) is expressed in the basal layer of the 
epidermis as well as in endothelial tissue and in smooth muscle cells, as part of the dermis (Wolf et 
al., 2010b).  
However, little is known about the expression of both S100-proteins in non-epithelial and immune 
cells. I could show a distinct expression of psoriasin (S100A7) and koebnerisin (S100A15) in 
monocytes, lymphocytes and neutrophils. Further koebnerisin (S100A15) could be shown to be 
expressed in human dermal fibroblasts, whereas psoriasin (S100A7) was not produced there (Figure 
3.1 and 3.2). 
The different expression of psoriasin (S100A7) and koebnerisin (S100A15) in resident skin and 
circulating immune cells may indicate their distinct functions and underline the need to distinguish 
both highly homolog S100-proteins. Expressed in fibroblasts, LC in the epidermis and dermal DCs 
koebnerisin (S100A15) showed a different expression pattern compared to psoriasin (S100A7) (Wolf 
et al., 2010b). Dermal fibroblasts and epidermal keratinocytes, are no classical immune cells, but 
these resident skin cells resume functions of classical circulating immune cells: activated, fibroblasts 
are important during extracellular matrix synthesis and express a big range of cytokines and 
chemokines. Furthermore, prior studies describe a regulation of hematopoietic cells by activated 
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fibroblasts to infiltrate into the tissue after damage (Sempowski et al., 1997; Smith et al., 1997). 
Thus, the expression of koebnerisin (S100A15) in fibroblast may activate the endothelia cells to 
express further cytokines and/or chemokines to maintain an inflammation.  
When expressed in leukocytes, the functional relevance of psoriasin (S100A7) and koebnerisin 
(S100A15) during inflammation might extend. Acting as chemoattractants for leukocytes and as 
‘alarmins’, psoriasin (S100A7) and koebnerisin (S100A15) induce the expression of pro-inflammatory 
cytokines (see chapter 4.3.1) and may also induce systemic inflammation.  
Further tissues, resident and circulating immune cells should be analyzed in continuing experiments 
to understand the complete homeostasis of both S100-proteins in men and to distinguish possible 
changes in disease.  
 
4.2 Regulation of psoriasin (S100A7) and koebnerisin (S100A15) 
S100-protein family members are encoded by a single transcript, with two exceptions so far: S100A4 
(Albertazzi et al., 1998; Ambartsumian et al., 1995; Lin et al., 2000) and koebnerisin (S100A15) (Wolf 
et al., 2003). The koebnerisin (S100A15) gene encodes for two alternative splice variants: a short 
transcript variant with 0.5 kb and a long variant with 4.4 kb (Wolf et al., 2010b). These two 
transcripts show a different regulation in healthy and psoriatic skin assuming that they do not share 
the same promotor region. Psoriasin (S100A7) and koebnerisin long splice variant (S100A15L) are 
regulated through conserved promoters at exon 1 whereas the short splice variant of koebnerisin 
(S100A15S) is regulated through exon 2, which explains their different regulation (Wolf et al., 2003). 
Despite more than 90% sequence homology, psoriasin (S100A7) and koebnerisin (S100A15) are 
functionally distinct and have to be distinguished. Psoriasin (S100A7) interacts with receptor for 
advanced glycation endproducts (RAGE) while koebnerisin (S100A15) acts through a yet unknown Gi-
protein coupled receptor (GiPCR) (Eyerich et al., 2009; Sabat et al., 2007). The regulation may 
explain the different expression of the high homolog proteins psoriasin (S100A7) and koebnerisin 
(S100A15) and may indicate the different functions and the important role of both S100-proteins 
during inflammation. 
4.2.1 Psoriasin (S100A7), koebnerisin (S100A15) and inflammasome associated proteins in disease 
susceptible skin and manifest psoriasis  
Psoriasin (S100A7) and koebnerisin (S100A15) are encoded within the S100 gene cluster on the 
psoriasis susceptibility locus 4 (PSORS4, Epidermal Differentiation Complex, chromosome 1q21), 
thus they are considered disease candidate genes (Hardas et al., 1996; Semprini et al., 1999; 
Semprini et al., 2002). Both S100-proteins were first time described up-regulated in chronic inflamed 
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psoriatic skin (Madsen et al., 1991; Wolf et al., 2003). But little is known about their expression and 
function in non-lesional psoriatic skin compared to healthy skin and psoriatic lesions.  
Psoriasin (S100A7) as well as koebnerisin (S100A15) were strongly up-regulated in lesional skin 
compared to the healthy controls. Already in healthy-looking non-lesional skin of patients with 
psoriasis a slight increased expression of both S100-proteins could be detected (Figure 3.3 and 3.4).  
In healthy looking skin of patients with psoriasis, psoriatic lesions can be induced upon slight 
mechanical trigger, called koebner phenomenon (Ghadially et al., 1996; Kuner et al., 2003). Evidence 
that the slight increased S100-levels in non-lesional skin are responsible for the susceptibility gives a 
psoriasis mouse model. Compared to human in rodent psoriasin (S100A7) and koebnerisin 
(S100A15) are combined in the mS100a7a15 protein. In the study it has been shown that 
mS100a7a15 interacts with RAGE, and mediates a cutaneous inflammation. However, healthy 
looking skin of mice that constitutively over-express mS100a7a15 imitates non-lesional psoriatic 
skin. Small mechanical or chemical trigger results in local induced inflammation on murine skin, the 
same can be seen in lesional psoriatic skin in men and is known as the koebner phenomenon. Thus 
the murine skin, like human skin, is primed for a Th1/Th17 inflammatory response IL-17A, TNFα and 
IL-1 are up-regulated, whereas IL-4 not (Wolf et al., 2010a).  
The pro-inflammatory IL-1β is a very potent cytokine and regulates the Th17 cell differentiation 
(Ghoreschi et al., 2010). Expressed as a precursor it has to be cleaved by pro-inflammatory caspases 
that in turn get activated by big cytosolic protein complexes called inflammasomes. The first 
identified member of the NOD-like-receptor (NLR) family that is able to form a large protein complex 
is the NACHT, LRR and PYD domains-containing protein1 (NALP1) (Martinon et al., 2002). To date 
more inflammasome complexes are described, like NALP3 or absent in melanoma 2 (AIM2). All 
inflammasomes have in common that they activate pro-inflammatory caspases. Activated pro-
inflammatory caspases cleave pro-IL-1β into its biologic active form, after activation the potent pro-
inflammatory cytokine is secreted into the extracellular space. The expression of the IL-1β in non-
lesional and lesional psoriatic skin is controversy discussed in literature. In the beginning of 1990s, 
Cooper et al. could show that the amount of IL-1 activity is reduced in lesional psoriatic skin, 
surprisingly IL-1β is increased but non-functional, whereas the constitutive IL-1α level is decreased in 
lesional psoriatic skin compared to healthy controls (Cooper et al., 1990). Around 7 years later an 
increased expression of IL-1β in lesional and no regulation in non-lesional psoriatic skin compared to 
healthy controls is detected, but the activity is not tested (Bonifati et al., 1997). 
In this study I could show that in lesional psoriatic skin the IL-1β, caspase-1, caspase-5, NALP3 and 
AIM2 gene levels were up-regulated, this could be confirmed by literature (Dombrowski et al., 2011; 
Johansen et al., 2007; Salskov-Iversen et al., 2011; Uyemura et al., 1993). However, non-lesional skin 
of patients with psoriasis showed a different expression pattern compared to healthy and lesional 
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psoriatic skin. A reduced expression of IL-1β, caspase-1 and caspase-5 could be measured whereas 
NALP1, NALP3 and AIM2 expression was not regulated in non-lesional psoriatic skin (Figure 3.10).  
The slight up-regulation of both S100-proteins in non-lesional psoriatic skin may indicate the 
capacity of psoriasin (S100A7) and/or koebnerisin (S100A15) to regulate pro-inflammatory cytokines 
and caspases. A previous study gives a hint which concentration of psoriasin (S100A7) is secreted by 
the healthy skin. The group of Regine Gläser could show that the secretion of psoriasin (S100A7) 
change with localization and age of the donor. Under the age of 20, the mean of secreted psoriasin 
(S100A7) lay around 3 ng/ml and increased with the age of 20 up to 60 years to an amount of 10 
ng/ml (Wittersheim et al., 2013). However, the study does not discriminate between psoriasin 
(S100A7) and koebnerisin (S100A15) but because of their high homonology they should be specified. 
Nevertheless, these results indicate that stimulation with 100 ng/ml psoriasin (S100A7) may imitate 
the situation in non-lesional skin. Comparing analysis for koebnerisin (S100A15) should be prepared 
in further studies, additional dose-dependent analysis of psoriasin (S100A7) and koebnerisin 
(S100A15) should be prepared next.  
First identified in 1995, caspase-5 was described in HeLa cells as a pro-apoptotic caspase (Munday et 
al., 1995), but in further reports it was shown that caspase-5 is not the main inducer of apoptosis by 
inducing cell stress in human retinal pigment epithelial cells (Bian et al., 2011). Described in 2001, 
the caspase-5 activation can result in apoptosis and inflammation (Martinon et al., 2001). Pro-
inflammatory caspases cleave pro-IL-1β but the expression in different tissues was not clarified for a 
long time. In 2007, Raymond et al. examined pro-inflammatory caspases in human skin, but they 
could not detect caspase-5 (Raymond et al., 2007). Some years later, further working groups showed 
an expression, healthy skin was used as a control (Salskov-Iversen et al., 2011).  
I could show an increased caspase-5 expression in psoriatic skin, however the localization of 
caspase-5 was not analyzed in previous reports (Salskov-Iversen et al., 2011) . Here I could show that 
only the epidermis expressed this protease, in healthy controls the expression was limited to the 
basal layer, whereas in psoriatic skin the expression of caspase-5 was found in the whole epidermis, 
thus also in differentiated keratinocytes (Figure 3.11). When comparing the histological 
immunoflourescent staining in the skin of caspase-5 and psoriasin (S100A7) it is remarkable that 
there is probably no co-localization. The concentration of psoriasin (S100A7) in healthy skin is quite 
low because the S100-protein is mainly expressed in differentiated keratinocytes, whereas the 
caspase-5 expression is localized in the basal layer of the epidermis (compare Figure 3.1 and 3.11). 
These results may indicate a regulatory effect of psoriasin (S100A7) on the caspase-5 expression in a 
dose-dependent manner. In lesional psoriatic skin the expressions of both proteins were increased 
and located in the whole epidermis, thus a clear co-localization is suggested but should be analyzed 
in future studies.  
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Reasonably, psoriasin (S100A7) and koebnerisin (S100A15) can be used as marker for chronically 
inflamed psoriatic skin. Furthermore, both S100-proteins can serve as a psoriasis susceptibility 
marker, because of their up-regulation in non-lesional psoriatic skin. This feature may be used to 
identify patients with psoriasis before manifestation of the disease, thus the physical strain can be 
reduced. 
4.2.2 S100 regulation through cytokines 
Psoriasis is a pro-inflammatory skin disease and characterized by abnormal keratinocytes 
differentiation, proliferation, infiltration of immune cells into the skin (Terui et al., 2000). T cell 
derived IL-17A as well as IFNγ and IL-22 were shown to be up-regulated in plaques of patients with 
psoriasis compared to non-lesional controls (Lowes et al., 2008). IL-17A is expressed and secreted as 
a homodimer and binds to its receptor, IL-17AR. After receptor activation a big range of cytokines 
and chemokines are induced such as TNFα, IL-1β, IL-6 and IL-8 in monocytes further IL-6 and IL-8 in 
human keratinocytes (van Beelen et al., 2007). Known as a Th1/Th17 induced pro-inflammatory skin 
disease, the secretion of Th17 cytokines by T cells in psoriatic skin is a main player in the 
pathogenesis (Boniface et al., 2007; Gläser et al., 2009a; Lowes et al., 2007; Wilson et al., 2007), but 
the capacity of these psoriasis typical cytokines to induce psoriasin (S100A7) and/or koebnerisin 
(S100A15) in epidermal keratinocytes is unknown.  
Here I could demonstrate that Th17 and Th22 cytokines induce psoriasin (S100A7) and koebnerisin 
(S100A15) in human epidermal keratinocytes (Figure 3.5). Furthermore, I could show that the 
combined stimulation with IL-17A and TNFα strongly increased the expression of psoriasin (S100A7) 
and koebnerisin (S100A15) (Figure 3.6). These results indicate that the surrounding cytokine-milieu 
is very important for gene regulation. Psoriasis is described as a Th1/Th17 induced pro-inflammatory 
skin disease whereat also IFNγ is very important and increased in patients with psoriasis (Szegedi et 
al., 2003), thus the psoriatic skin epidermis is exposed to a mixed Th1/Th17 cytokine-milieu. The 
combined stimulation of IL-17A and IFNγ showed a synergistically induced expression of psoriasin 
(S100A7) and koebnerisin (S100A15) (Figure 3.7).  
Data indicate that psoriasin (S100A7) and koebnerisin (S100A15) are differentially induced by soluble 
mediators of Th17-differentiated lymphocytes, which reflects the differential expression pattern in 
the psoriatic epidermis (Gläser et al., 2009a; Wolf et al., 2007). Further IL-17 was identified as the 
main inducer of both S100-proteins after single stimulation with the tested Th17/Th22 cytokines.  
A previous study showed that psoriasin (S100A7) is induced by TNFα as well as by IL-17A, but the 
combined stimulation and the koebnerisin (S100A15) expression was not analyzed. The same study 
shows that the antimicrobial peptides hBD-2 and RNase7 are synergistically induced whereas hBD-3 
was just slightly increased after the combined stimulation of IL-17A and TNFα (Gläser et al., 2009a). 
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In a previous study, it could be shown that the combined stimulation of IL-17A and IFNγ induces 
beside psoriasin (S100A7) further antimicrobial peptides like hBD-2, hDB-3 and RNase7 
synergistically (Simanski et al., 2013). Further IFNγ and IL-17A seem to be very important against 
lung infection with Chlamydia muridarum (CM). The study was performed in murine lung epithelial 
cells (TH-1), and together these studies demonstrate the big range of IL-17A and IFNγ to induce host 
defence (Zhang et al., 2012). But also IL-17A alone seems to play a central role in host defence. 
Patients with a genetic defect in the IL-17RA (IL-17 receptor A) suffer for a chronic mucocutaneous 
candidiasis, a chronic infection of the skin, nail or mucosa caused by Candida albicans or S.aurus 
(Puel et al., 2011). Thus the surrounding cytokine-milieu seems to be very important for the 
regulation of antimicrobial peptides and induces host defence. 
 
Besides S100-peptides, psoriasis typical Th1/Th17 cytokines further regulate pro-inflammatory 
cytokines. In literature it is described that IFNγ but not TNFα induces the expression of the pro-
inflammatory caspase-1 and caspase-5 in human epidermal keratinocytes as well as in PBMCs. The 
group around Salskov-Iversen et al. shows a difference between the induction of caspase-5 in 
epidermal keratinocytes and PBMCs. While caspase-5 is induced by IFNγ and the combined 
stimulation of TNFα and IL-17A, the biggest induced expression in PBMCs is observed after 
stimulation with IFNγ and LPS, the same study shows that the caspase-5 gene expression is induced 
by translocalization of NF-κB (Lee and Kim, 2007; Salskov-Iversen et al., 2011). The single stimulation 
with IL-17A does not show a regulation on RNA level in human epidermal keratinocytes (Salskov-
Iversen et al., 2011). 
Here I could show that Th1 and Th17 cytokines induce pro-inflammatory cytokines differently: IL-1β 
was only induced after TNFα stimulation. However, an induction of caspase-1 and caspase-5 could 
be measured after IFNγ stimulation, whereas stimulation with IL-17A did not induce the tested 
cytokine or caspases. Interestingly, stimulation with TNFα led to a significant down-regulated NALP1 
gene level (Figure 3.12), this may show the strong need to regulate the constitutively expressed 
NALP1 in human epidermal keratinocytes.  
Furthermore I could demonstrate that the combined stimulation of IFNγ and IL-17A increased the IL-
1β and caspase-5 expression synergistically, whereas expression of caspase-1 showed just a slight 
up-regulation. However, a strong up-regulation of NALP3 and AIM2 could be measured after the 
single stimulation with IFNγ which was strongly decreased after additional stimulation with IL-17A 
(Figure 3.13). Data suggest that IL-17A shifts the IFNγ-induced inflammasome regulation and IL-1β 
production by epidermal keratinocytes thus a favour to the NALP1 inflammasome and its 
components. In the Th1/Th17 milieu caspase-5 was synergistically up-regulated and under the same 
conditions NALP3 and AIM2 were down-regulated.  
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Previous reports described that a related synergistic increased expression of IL-6 and IL-8 could be 
measured after stimulation with IL-17 and IFNγ (Teunissen et al., 1998), indicating a general 
mechanism in the Th1/Th17 milieu, interestingly the capacity of the combined Th1/Th17 stimulation 
to regulate IL-1β or pro-inflammatory caspases is not analyzed. 
Increasing evidence connects NALP1 to the pathogenesis of IL-1β-mediated Th17 auto-inflammatory 
diseases involving the skin, such as lupus erythematosus and psoriasis and should be further 
analyzed (Jin et al., 2007; Kurasawa et al., 2000; Salskov-Iversen et al., 2011) (see chapter 4.3.2)  
4.2.3 Psoriasin (S100A7) and koebnerisin (S100A15) are regulated by UVB irradiation  
The human skin is naturally exposed to UV irradiation, approximately 5% of the electromagnetic 
radiation arrives at the earth’s surface consisting of 90 - 95% UVA and 5 - 10% UVB radiation (Diffey, 
2002). The best seen effect of acute and chronic UV irradiation on skin is the sunburn, skin aging and 
the potential to induce skin cancer. The skin immune system is modulated by UVB light e.g. the 
number of Langerhans cells (LC) and T cells are reduced after irradiation (Chapman et al., 1995; 
Euvrard et al., 2003) but after a time period LC and T cells as well as neutrophils and macrophages 
infiltrate into the epidermis, resulting in an increased number of immune cells (Chapman et al., 
1995; Norval, 2006; Termorshuizen et al., 2002). Beside the adaptive immunity, the innate immune 
system is activated after UVB irradiation, much faster but non-specific. Cytokines, complement 
system and antimicrobial peptides are described to be up-regulated after UVB irradiation in the skin 
and in human epidermal keratinocytes (Braff and Gallo, 2006; Gläser et al., 2009b). Thus, UVB has a 
strong impact on innate and adaptive immunity and was used as a model for acute induced 
inflammation in this study. 
For the first time, Gläser et al. described an increased expression of different classes of keratinocyte-
derived antimicrobial-peptides like defensins, RNase and S100-proteins in vitro and in vivo after UV 
irradiation in human epidermal keratinocytes on mRNA and protein level, whereas the in vitro data 
were much more heterogeneous compared to the data generated from patients (Gläser et al., 
2009b). Furthermore, this working group showed that the AMPs are mostly expressed in the upper 
epidermal layers where the first contact with pathogens takes place. Previous studies showed an 
increased expression of different AMPs after UV radiation, but the highly homologous psoriasin 
(S100A7) and koebnerisin (S100A15) were not distinguished (Gambichler et al., 2006; Seo et al., 
2001).  
I could show that after UVB irradiation the highly homologous proteins psoriasin (S100A7) and 
koebnerisin (S100A15) were time- and dose-dependently induced, on RNA and protein level, 
furthermore, RAGE was up-regulated after irradiation, but a co-regulation of psoriasin (S100A7) and 
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its receptor could not be detected (Figure 3.8 and Figure 3.9). The S100 expression pattern indicates 
a prominent role for both S100-proteins after UVB irradiation.  
UV irradiation can result in a barrier disruption of the epidermis (Lande et al., 2007), thus pathogens 
can easily invade. An up-regulated psoriasin (S100A7) and koebnerisin (S100A15) level may reduce 
the infiltration of pathogens by acting as AMPs and as ‘alarmins’ to induce pro-inflammatory 
cytokines (see chapter 4.3.1) and as chemoattractants for leucocytes (Hegyi et al., 2012; Wolf et al., 
2008). Beside S100-proteins, an increased level of further AMPs may trigger immune-mediated 
diseases, like it is described for LL-37 in the pathogenesis for psoriasis (Lande et al., 2007). 
RAGE has been described as a multiligand receptor that induces multiple downstream signalling 
pathways after activation. The dose- and time-dependant UVB induced expression pattern of 
psoriasin (S100A7) and RAGE might be a self-regulation of keratinocytes. It is described that ligand 
binding results in RAGE up-regulation (Sorci et al., 2013) thus an expression of receptor and its ligand 
at the same time was prevented, to regulate and reduce the inflammation. Because of their 
multifunctional capacity, expression of psoriasin (S100A7) and koebnerisin (S100A15) and their 
receptors might be controlled very strictly by keratinocytes and should be analyzed in further 
experiments. 
Taken together, these results showed that endogenous-, like different Th1 and Th17-cytokines, and 
exogenous factors, like UVB irradiation, induce the S100 expression in human epidermal 
keratinocytes. Based on pro- or auto-inflammatory skin diseases like Lichen planus, Atopic dermatitis 
and/or psoriasis it should be further analyzed in detail which cytokines and cytokine-milieus are 
responsible for S100-protein regulation.  
 
4.3 Function of psoriasin (S100A7) and koebnerisin (S100A15)  
The skin is one of the largest barrier organs and a defense against infiltrating microorganisms is 
required. Keratinocytes, the predominant cells of the epidermis, are secreting their own antibiotics, 
so called ‘antimicrobial peptides’ (AMPs), the function of these proteins are highly conserved and 
can be found in plants, invertebrates up to humans, who express and secrete a variety of 
antimicrobial peptides (Reddy et al., 2004; Schauber and Gallo, 2008). AMPs are a heterogenic group 
of small peptides which are subdivided by their chemical and biological characteristics (Brogden, 
2005). A very well-known AMP-family are the S100-proteins, first described in 1965 and named by 
Moore because of their special characteristic to be 100% soluble in ammonium sulfate at a neutral 
pH (Moore, 1965). This family has a very wide antimicrobial effect e.g. the heterodimer of 
S100A8/S100A9 (calprotectin) that acts against the fungi C. albicans (Clohessy and Golden, 1995; 
Sohnle et al., 2000). Two members, psoriasin (S100A7) and koebnerisin (S100A15), build their own 
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S100-subfamily because of their high homology. Secreted into the extra cellular space, psoriasin 
(S100A7) and koebnerisin (S100A15) act as AMPs. Psoriasin (S100A7) is mainly located in areas with 
high bacterial colonization, like hair follicles or the nose, and described as an effective killer for E. 
coli, already in very low doses (Gläser et al., 2005). However, koebnerisin (S100A15) seems to be 
induced beside E. coli additionally after S.aureus and P.aeroginosa, thereby a wide antimicrobial 
spectrum is anticipated compared to psoriasin (S100A7) (Büchau and Gallo, 2007).  
4.3.1 Psoriasin (S100A7) and koebnerisin (S100A15) act as ‘alarmins’  
‘Alarmins’ are usually constitutively expressed and can be induced in leukocytes and epithelial cells, 
including keratinocytes, and are described to be rapidly released upon pathogen invasion or tissue 
injury. Furthermore, pathogen-associated molecular patterns (PAMPs), highly conserved motives of 
pathogens that are recognized by the immune system, like lipopolysaccharides (LPS), component of 
the outer membrane of gram negative bacteria, or pro-inflammatory-cytokines like IL-1, TNF or IFN 
can induce the expression of many ‘alarmins’ (Yang et al., 2004; Yang and Oppenheim, 2009b). 
‘Alarmins’ are defined as endogenous mediators that can recruit antigen-presenting cells (AMPs) and 
facilitate the induction of an immune response. The group of ‘alarmins’ include defensins, 
cathelicidin, eosinophil-derived neurotoxin (EDN) and high-mobility group box 1 (HMGB1) protein 
(Yang et al., 2009a; Yang and Oppenheim, 2009b). The function as self-danger molecules is highly 
conserved in the evolution and is described for different antimicrobial peptides (Harder et al., 2007; 
Wolf et al., 2010a).  
In this study, I could introduce another protein sub-family into the group of ‘alarmins’: psoriasin 
(S100A7) and koebnerisin (S100A15). Both S100-proteins primed human epidermal keratinocytes to 
increase the expression of pro-inflammatory cytokines like TNFα, IL-6 and IL-8, thus their function as 
‘alarmins’ is described. At the same time the expression of the antimicrobial peptide hBD-2 was 
suppressed (Figure 3.17). Data indicate that psoriasin (S100A7) and koebnerisin (S100A15) become 
important for connecting innate and adaptive immunity.  
Further studies demonstrate that psoriasin (S100A7) treatment alone induced the expression of IL-6 
and IL-8 in PBMCs and neutrophils (Kvarnhammar et al., 2012; Zheng et al., 2008), but the combined 
stimulation with koebnerisin (S100A15) was not analyzed. The increased expression of pro-
inflammatory cytokines after the combined stimulation with both S100-proteins can be caused by 
regulation through their different receptors (Eyerich et al., 2009; Sabat et al., 2007). The decreased 
expression of further AMPs after stimulation with psoriasin (S100A7) and koebnerisin (S100A15) 
may indicate the strong need to control the regulation. Expressed in leucocytes (see chapter 4.1) the 
impact of psoriasin (S100A7) and koebnerisin (S100A15) as multifunctional proteins may increase.  
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Besides psoriasin (S100A7) and koebnerisin (S100A15), further AMPs have different functions. The 
AMP LL-37 has been shown to act as chemoattractant for monocytes, neutrophils and mast cells 
(Ayabe et al., 2000; Gudmundsson and Agerberth, 1999; Niyonsaba et al., 2002). Also for α- and β-
defensins a chemotactic function is described (Bardan et al., 2004). Because of their multifunctional 
feature the capacity of psoriasin (S100A7) and koebnerisin (S100A15) to regulate pro-inflammatory 
cytokines like IL-1β was analyzed next.  
 
To activate the inflammasome two signals are needed. After binding of e.g. LPS to its receptor TLR4 
translocalization of NF-κB into the nucleus is induced and the expression of the inactive pro-IL-1β 
and further pro-inflammatory cytokines are up-regulated, thus keratinocytes are primed. The second 
stimuli are intracellular located DAMPs e.g. increased amounts of adenosine triphosphate (ATP) or 
PAMPs like bacterial toxins that activate the inflammasome, thus cause an oligomerization and the 
complex develops. The oligomerized inflammasome complex recruits ASC, which in turn bind the 
inactive pro-caspase-1 and through a proteolytic cleavage the pro-caspase gets activated and 
cleaves the precursor pro-IL-1β into its biologic active form. The mature IL-1β is secreted into the 
extracellular space and induces further signal transduction via its specific IL-1 receptor (Sidiropoulos 
et al., 2008). Two well-known activators of the NALP1 inflammasome are anthrax lethal factor and 
muramyl dipeptide (MDP) (Girardin et al., 2003; Hsu et al., 2008). In many auto-inflammatory 
diseases, like cryopyrin-associated periodic syndrome (CAPS), familial mediterranean fever (FMF), 
rheumatoid arthritis and more, an up-regulated IL-1β gene and protein level could be measured 
(Dinarello, 2011).  
4.3.2 Psoriasin (S100A7) is a key regulator of IL-1β and pro-inflammatory caspases under the 
Th1/Th17 cytokine-milieu 
In 2007, Harder et al. described psoriasin (S100A7) and koebnerisin (S100A15) as links between 
innate and adaptive immunity (Harder et al., 2007). Furthermore both S100-proteins are described 
as multifunctional peptides but to date nothing is known about their capacity to regulate the 
inflammasome activity. 
Here I could demonstrate a diverse immunoregulatory capacity of psoriasin (S100A7). Silencing the 
S100-protein by small interfering (si)RNA and stimulation with IFNγ resulted in up-regulation of IL-1β 
indicating an IL-1β suppressing effect. The compared regulation could be measured within the 
expression of pro-inflammatory caspase-1 and caspase-5. Both caspases were down-regulated after 
silencing psoriasin (S100A7) and IFNγ treatment. Additional stimulation with IL-17A showed a 
stronger down-regulated RNA level of both pro-inflammatory caspases, the IL-1β RNA level was 
slightly up-regulated (Figure 3.15). Data suggest a pro-inflammatory regulation of psoriasin (S100A7) 
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in human epidermal keratinocytes. However, previous findings showed an anti-inflammatory effect 
of IL-17A stimulation on protein level. The different regulation can be caused by the different 
cytokine-milieu. Shown before, stimulation with IL-17A resulted in an increased expression of 
caspase-5, whereas the expression of AIM2 was massively decreased. Furthermore, silencing 
psoriasin (S100A7) by siRNA implicates that no protein is left in the cytosol, thus a changed milieu 
can be the reason of pro-inflammatory capacity of IL-17A.  
After single stimulation with IFNγ and silencing psoriasin (S100A7) the expression level of NALP1 and 
NALP3 were up-regulated in contrast to the down-regulated AIM2 RNA level. The combined 
stimulation of IFNγ, IL-17A and silenced psoriasin (S100A7) resulted in down-regulation of the 
inflammasome complexes NALP3 and AIM2, whereas the expression of NALP1 was not influenced 
(Figure 3.16). These results showed a variable psoriasin (S100A7) dependent regulation of pro-
inflammatory cytokines, caspases and inflammasome complexes under different cytokine 
conditions. Expression of NALP3 showed a diverse regulation in different cytokine-milieus, this 
demonstrates how important it is to analyze the involved mediators of a pro-inflammatory disease 
in detail to obtain the best reconstruction in vitro. 
Beside plaque psoriasis atopic dermatitis (AD) is another common inflammatory skin disease. 
Psoriasis and AD are multifactorial skin diseases with an involvement of innate and adaptive 
immunity, based on a genetic disposition and are both triggered by environmental factors (Guttman-
Yassky et al., 2008). However, a big difference between these two inflammatory skin diseases is the 
surrounding cytokine-milieu. AD is described as Th2 cytokine induced disease with a shift to Th1 
cytokines in the chronic phase (Ong and Leung, 2006) whereas psoriasis is a Th1/Th17 mediated skin 
disease (Lowes et al., 2008). The difference in the cytokine-milieu may explain the reduced 
expression of antimicrobial peptides in lesional AD compared to lesional psoriasis resulting in an 
increased colonization on skin of patients with AD (Gambichler et al., 2008; Wollenberg and Klein, 
2007). Nevertheless, it is shown that the psoriasin (S100A7) expression in lesional AD is slightly 
increased compared to healthy controls (Gläser et al., 2009a). Furthermore, polymorphisms in NLR 
genes in atopic dermatitis are analyzed. This study describes that single nucleotide polymorphisms 
(SNPs) are found, beside others, in the promotor region of NALP1 (Macaluso et al., 2007). Based on 
current literature the NALP1 seemed to be very important in auto-immune and auto-inflammatory 
skin diseases, further analysis shows polymorphisms in NALP1 are involved in the predisposition of 
systemic lupus erythematosus (Pontillo et al., 2012). 
These results and the literature show how important the influence of the surrounding of Th17-
cytokines is. Furthermore, the multifunctional S100-proteins should be analyzed in further Th17-
mediated diseases like systemic lupus erythematosus or lichen ruber. But not only auto-immune and 
auto-inflammatory skin diseases can be affected, here I could show that leukocytes, monocytes and 
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neutrophils also express psoriasin (S100A7) and koebnerisin (S100A15) (see chapter 4.1), indicating 
an increasing relevance of the multifunctional S100-proteins. 
4.3.3 Inflammasome activity in epidermal keratinocytes 
The innate immune system recognizes invading pathogens and their high conserved motives by their 
germ line-encoded pattern-recognition-receptors (PRR) which include the membrane bounded Toll-
like receptors (TLR), the cytosolic RIG-I receptors (RLRs), the NOD-like receptors (NLRs) and still 
poorly described cytosolic DNA sensor like the stimulator of interferon genes (STING) (Baccala et al., 
2009; Medzhitov, 2007; Schroder and Tschopp, 2010; Takeuchi and Akira, 2010; Tsuchida et al., 
2010; Yoneyama and Fujita, 2009). Cytosolic double stranded (ds)DNA, independent of origin, e.g. 
DNA derived from DNA viruses or bacterial DNA as well as damaged host cells trigger the innate 
immune system (Hornung and Latz, 2010; Ishii et al., 2006; Nagata et al., 2010; Yanai et al., 2009). 
TLR9 is described to identify mostly CpG DNA motives derived from viruses and bacteria (Hemmi et 
al., 2000), further AT-rich dsDNA motives are recognized by the RLR member RIG-I caused by an 
induced expression of RNA-polymerase III (Ablasser et al., 2009). Recently, free cytosolic dsDNA has 
been shown to activate the AIM2 inflammasome, which contains the HIN200 dsDNA sensor domain 
and is functionally active in psoriatic keratinocytes (Burckstummer et al., 2009; Fernandes-Alnemri 
et al., 2009; Hornung et al., 2009; Roberts et al., 2009). Several danger-associated molecular 
patterns have been discovered to trigger inflammasome formation (Stutz et al., 2009). Under 
pathological conditions intracellular dsDNA can be detected in the cytosol (Charles et al., 2000; 
Pisetsky et al., 1990), e.g. in auto-inflammatory psoriasis. Previous study showed that an increased 
amount of cytosolic dsDNA can be detected in psoriatic skin compared to healthy controls 
(Dombrowski et al., 2011), furthermore IL-1β is increased in keratinocytes. Nevertheless, little is 
known which inflammasome complexes are involved and which components are regulated upon 
dsDNA binding.  
To activate the inflammasome complex the combined stimulation of IFNγ and dsDNA were needed, 
neither single stimulation with IFNγ or dsDNA nor DNase digested dsDNA resulted in a release of IL-
1β into the culture supernatant (Figure 3.18). The same set of experiments was analyzed by Western 
blot to investigate where pro-inflammatory caspases got activated (Figure 3.19). Surprisingly in the 
cell lysates cleaved caspase-1 and caspase-5 could be found in the DNase digested dsDNA probes, in 
the supernatant only cleaved caspase-1 could be detected in the dsDNA treated probes. 
Very little can be found in current literatue about the cleaved caspase-5 and its function in man. 
However, also Salskov-Iverson et al. are not able to detect cleaved caspase-5 in skin probes of 
patiens with psoriasis. Previous studies on the caspase-5 murine homolog caspase-11 suggest that 
the cleaved protein might not be essential or unstable, as suggeted by Schauvliege et al (Kang et al., 
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2002; Schauvliege et al., 2002). Li et al. show that murine macrophages lacking caspase-11 are not 
able to migrate or phagocytose (Li et al., 2007), these results may indicate further functions also for 
the human caspase-5 and should be analyzed in following experiments. This suggests that the 
expression of caspase-5 depends on the cell type. Caspase-5 is induced very strongy after LPS in 
PBMCs, just a very slightly increased expression could be measured in epidermal keratinocytes 
(Salskov-Iversen et al., 2011).  
 
Further results showed that IL-17A suppressed IL-1β secretin in human epidermal keratinocytes. 
Stimulated with IFNγ, TNFα, IL-17A and transfection with dsDNA resulted in a decreased release of 
IL-1β in the supernatant (Figure 3.20). This effect could be caused by the reduced expression of 
dsDNA sensing AIM2 inflammasome after stimulation with IFNγ and IL-17A (Figure 3.13). Previous 
studies also show an anti-inflammatory effect of IL-17A in experimental gastritis in mice (Otani et al., 
2009). In this study I could demonstrate that psoriasin (S100A7) was able to substitute the TNFα 
priming effect of the inflammasome, whereas koebnerisin (S100A15) was not, indicating a strong 
pro-inflammatory function under the psoriatic Th1/Th17 cytokine-milieu of psoriasin (S100A7) 
(Figure 3.21). Although, psoriasin (S100A7) and koebnerisin (S100A15) have a very high sequence 
homology (<90%) (Wolf et al., 2003), it is important to discriminate these two proteins. 
Again, the different functions of psoriasin (S100A7) and koebnerisin (S100A15) can be caused their 
different receptor regulation. Psoriasin (S100A7) is known to regulate through RAGE, activation of 
RAGE results in an interaction with myeloid differentiation primary response gene (88) (MYD88) and 
toll-interleukin 1 receptor (TIR) domain containing adaptor protein (TIRAP) resulting in an increased 
expression of pro-inflammatory cytokines (Hreggvidsdottir et al., 2009; Ivanov et al., 2007; Qin et al., 
2009). 
 
To analyze if the NALP1 inflammasome is responsible for an IL-1β release, human keratinocytes were 
stimulated with TNFα and IFNγ to prime and transfected with dsDNA to activate the inflammasome 
complex. Silencing the NALP1 inflammasome by siRNA resulted in a decreased release of mature IL-
1β in the supernatants. However, additionally stimulation with psoriasin (S100A7) increase the 
amount of mature IL-1β in the supernatants, indicating that psoriasin (S100A7) has a pro-
inflammatory effect independent of the NALP1 inflammasome (Figure 3.22). Data showed, that 
silencing NALP1 by siRNA, followed by priming and activation of the inflammasome, reduced the 
amount of mature IL-1β in the supernatants significantly what I read out as a sign that not only the 
AIM2 but also the NALP1 inflammasome has an influence on the dsDNA-dependent release of IL-1β 
by human epidermal keratinocyte (Figure 3.22 and 3.23).  
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Described as an inflammasome that gets activated after treatment with Bacillus anthracis and 
muramyl dipeptide (Hsu et al., 2008) here I could describe dsDNA as a new activator of the NALP1 
inflammasome. Psoriasin (S100A7) is co-induced with NALP1 associated caspase-1 and caspase-5 by 
IFNγ in epidermal keratinocytes and enhanced the IL-1β release by keratinocytes through regulation 
of NALP1 associated caspase-1 and caspase-5 (Gläser et al., 2005; Simanski et al., 2013). 
Furthermore, these data suggest that the Th1/Th17 milieu also influences the balance between the 
inflammasomes in keratinocytes. IL-17A strongly amplified pro- IL-1β and the NALP1-specific 
caspase-5 and slightly induced caspase-1 in keratinocytes.  
 
NALP1 can be found in different tissues and cell types: amongst others in the brain, less in epithelial 
tissues, testis, alveolar macrophages, peripheral blood mononuclear cells (PBMCs) and lymphocytes 
(Kummer et al., 2007). The NALP1 inflammasome is constitutively expressed in keratinocytes 
compared to e.g. NALP3, which has to be induced (Faustin and Reed, 2008; Feldmeyer et al., 2007). 
Recent evidence underlines the relevance of NALP1 inflammasome activity for the pathogenesis of 
Th17-mediated autoimmune diseases. Gene polymorphisms in the NALP1 complex are linked to 
increased NALP1 inflammasome activity and present an independent risk factor for their 
development are found in patients with systemic lupus eythematosus, rheumatoid arthritis, 
inflammatory bowel disease, autoimmune thyroid diseases, Type 1 diabetes and Addison's disease 
(Dwivedi et al., 2013; Jin et al., 2007; Pontillo et al., 2012). The role of NALP1 inflammasome activity 
for the pathogenesis of Th17-mediated autoimmune diseases is increasingly understood, such as 
lupus erythematosus, rheumatoid arthritis, and type I diabetes (Alzabin et al., 2012; Dolff et al., 
2010; Magitta et al., 2009). In Th17-mediated auto-inflammatory diseases that affect the skin, 
psoriasin (S100A7) is co-regulated with NALP1 in the epidermis of patients with psoriasis and lupus 
erythematosus (Kreuter et al., 2011; Salskov-Iversen et al., 2011). The observed IL-17A-mediated 
psoriasin (S100A7) expression and the psoriasin (S100A7)-regulated NALP1 inflammasome activity in 
keratinocytes suggest a pathogenetic link in NALP1 triggered diseases. Anti-IL-17A blocks psoriasin 
(S100A7) expression in epidermal keratinocytes (see chapter 4.1) and the success of Th17 interfering 
therapies in NALP1 associated diseases, such as psoriasis supports this hypothesis (McGovern et al., 
2012; Salskov-Iversen et al., 2011; Zwicker et al., 2012). Cytosolic dsDNA is also present in other 
autoimmune diseases and might trigger the NALP1 inflammasome activation, such as systemic lupus 
erythematosus (Watanabe et al., 1985). This mechanism is different from pathogenic mechanisms 
observed in autoinflammation through other dsDNA sensors, such as TLR9 (Rosenstiel et al., 2007).  
Recently, it is shown that also RAGE promotes DNA up-take into endosomes resulting in an 
activation of TLR9, located there. These findings are confirmed by RAGE deficient mice that are 
unable to induce an inflammation to response to DNA treatment (Sirois et al., 2013). Furthermore, 
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the AMPs β-defensin 2 and 3 are linked to the up-take of self-DNA and promote inflammation in 
dendritic cells (Tewary et al., 2013). 
The biologics Ixekizumab or Secukinumab are tested in clinical phase III blocking directly IL-17A but 
an increasing IL-1β expression of treated patients could not be found in current literature (Crow, 
2012). These therapies are used for moderate-to-serve treatment of plaque psoriasis, thus the 
amounts of cytokines are very high, and in this study lower cytokine concentrations were used. The 
results from the clinical studies demonstrate the high importance to analyze the composition of 
cytokines and immune mediators in the different diseases to generate therapies that antagonize 
origin of disease not only the symptoms. 
 
Taken together, these results showed that the cytokine-milieu is very important for the regulation of 
the different inflammasome components, complexes and its substrates. In psoriasis IL-1β is a very 
important but low expressed player, which correlates with the results that patients treated with 
anakinra, an IL-1β blocker, were not very successful. The typical psoriatic Th1/Th17 cytokine-milieu 
favours the NALP1 inflammasome component caspase-5, this caspase belong exclusively to NALP1. 
At the same time, other inflammasome complexes like AIM2 and NALP3 were down-regulated. 
Further stimulation with IL-17A led to strongly decreased release of mature IL-1β, thus the Th17 
cytokine had an anti-inflammatory effect in this milieu. The Th1/Th17 cytokine-milieu together with 
the increasing expression of psoriasin (S100A7) and koebnerisin (S100A15) catalyze the vicious circle 
of inflammation: keratinocytes get activated to produce and secrete pro-inflammatory cytokines and 
AMPs that act as chemoattractants for leukocytes and neutrophils (Guttman-Yassky et al., 2011; 
Hegyi et al., 2012; Wilsmann-Theis et al., 2008; Wolf et al., 2008). 
Furthermore, this study showed two new functions of psoriasin (S100A7) and koebnerisin 
(S100A15). Together both S100-proteins act as ‘alarmins’ and amplify the inflammation by an 
increased expression of pro-inflammatory cytokines. Additionally, psoriasin (S100A7) was 
characterized as an inflammasome regulator by controlling the IL-1β release through regulation of 
inflammasome dependent caspases.  
4.3.4 Psoriasin (S100A7) and koebnerisin (S100A15) in acute induced inflammation  
The NALP3 inflammasome has been described to be active after UVB irradiation, resulting in a 
calcium dependent release of mature IL-1β. Silencing the NALP3 inflammasome complex resulted in 
a significantly reduced amount of IL-1β (Feldmeyer et al., 2007). However, activation of caspases 
after UVB irradiation are often described for pro-apoptotic caspase-3 or caspase-9 (Sitailo et al., 
2002; Slee et al., 2000), whereas a direct regulation of pro-inflammatory cytokines is very poorly 
described in the current literature. Described to be up-regulated upon UVB irradiation (Gläser et al., 
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2009b), little is known about the capacity of multifunctional psoriasin (S100A7) and/or koebnerisin 
(S100A15) to regulate inflammasome activation by UVB. The NALP1 inflammasome seemed to be 
important upon UVB induced IL-1β release, but silencing the associated caspase-5 was not analyzed 
(Feldmeyer et al., 2007). 
In the current study, stimulation with UVB alone was sufficient to obtain mature IL-1β, but the 
release was increased with additionally IFNγ treatment. Further, stimulation with psoriasin (S100A7) 
or koebnerisin (S100A15) resulted just in a minimal change of the IFNγ and UVB induced IL-1β level 
(Figure 3.24). Silencing the different inflammasome components by siRNA gave insights into the 
mechanisms to release IL-1β into the supernatant. Silencing caspase-1 and NALP1 resulted in a 
decreased amount of mature IL-1β, whereas silencing caspase-5 or psoriasin (S100A7) did not have 
an effect. However, silencing koebnerisin (S100A15) increased the amount of released IL-1β, 
indicating an anti-inflammatory effect of koebnerisin (S100A15) after UVB irradiation (Figure 3.25). 
The working group around Feldmeyer et al. describe that silencing NALP1, caspase-1 and NALP3 
resulted in a decreased release of IL-1β in the supernatant but the used UVB dose was much higher 
compared to the dose that was used in this current study.  
This study silenced caspase-5 and did not see a decreased amount of IL-1β after the high dose UVB, 
also in these studies silencing caspase-5 did not show a changed IL-1β level in the supernatant after 
low-dose UVB. Low dose UVB induces little cell stress, thus an inflammation, whereas high dose UVB 
induces severe damages and apoptosis is induced. Also pyroptosis is a described scenario after UV-
irradiation, here the cells burst and all pro-inflammatory cytokines are released in the extracellular 
space. By binding of pro-inflammatory cytokine to their receptors the inflammation is facilitated. But 
pro-IL-1β cannot bind its receptor without cleavage. Gelatinases b (MMP9) is located in the 
extracellular space and known to cleave pro-IL-1β thus the activated cytokine binds its receptor IL-
1R and amplify the inflammation (Schonbeck et al., 1998).  
The different UVB doses might be important, because UVB is known to induce cell stress, depending 
on the dose cells express pro-inflammatory cytokines. Further analysis showed that pro-
inflammatory caspase-4 is required for activation of inflammasomes in human epidermal 
keratinocytes after high dose of nearly 100 mJ/cm2.  
Together these results showed that the endogenous factor UVB activates the inflammasome thus 
pro-IL-1β is cleaved. A direct effect of psoriasin (S100A7) and/or koebnerisin (S100A15) on 
inflammasome activation by UVB was not detected. 
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4.4 Targeting S100-proteins through anti-inflammatory therapies 
Psoriasin (S100A7) and koebnerisin (S100A15) are multifunctional proteins first discovered strongly 
up-regulated in psoriatic skin (Madsen et al., 1991; Wolf et al., 2003). Both S100-proteins show a 
synergistic antimicrobial function in the skin (Büchau and Gallo, 2007; Gläser et al., 2005) because 
they are signaling through two different receptors, psoriasin (S100A7) is a ligand of RAGE, whereas 
the Gi-protein coupled receptor of koebnerisin (S100A15) is still unknown, thus also their effect as 
chemoattractants is amplified (Wolf et al., 2008; Wolf et al., 2010b). Furthermore, I could show that 
the multifunctional psoriasin (S100A7) and koebnerisin (S100A15) act as ‘alarmins’ and facilitate the 
inflammation by regulation pro-inflammatory cytokines and different antimicrobial peptides (see 
chapter 4.3.1). In addition, psoriasin (S100A7) controls the IL-1β release in human epidermal 
keratinocytes through regulation of the inflammasome associated caspases in a defined Th1/Th17 
cytokine-milieu (see chapter 4.3.2). 
4.4.1 T cell supernatant of patients with psoriasis induce S100 expression 
Described as a Th1/Th17 induced pro-inflammatory skin disease a wide range of cytokines like t cell 
derived IL-17A, IFNγ, IL-22 and many more are shown to be up-regulated in lesions of patients with 
psoriasis (Lowes et al., 2008). But a detailed regulation of cytokines and further inflammation 
regulators is not described. 
Here I could demonstrate that the supernatant of dermal t cells isolated form patients with psoriasis 
induced the expression of the multifunctional psoriasin (S100A7) and koebnerisin (S100A15) in 
keratinocytes (Figure 3.26). Whereas previous results showed that Th1, Th17 and Th22 cytokines 
were responsible for an increased RNA level (Figure 3.6 and 3.7).  
Systemically patients with psoriasis are treated with biologics, recombinant fusion proteins or 
monoclonal antibodies. Blocking TNFα with Etanercept is a common treatment for patients with 
moderate to serve psoriasis. This recombinant human TNF receptor fusion protein antagonizes the 
effect of endogenous TNFα caused by a higher affinity of TNFα to Etanercept then to the TNF-
receptor (Mease et al., 2000). Also neutralizing IL-17A by the biologic Ixekizumab, a humanized IgG 
monoclonal antibody is also used as a systemically psoriasis treatment (Leonardi et al., 2012; Martin 
et al., 2013). Little is known about the regulation of other inflammation mediators like S100-
proteins. 
To analyze in detail which cytokine of the T cell supernatant was responsible for the increased 
expression of both S100-proteins, IL-17A and TNFα were blocked with specific blocking antibodies. 
The blocking of IL-17A but not of TNFα led to a decreased expression of psoriasin (S100A7) and 
koebnerisin (S100A15) after stimulation with T cell supernatants in human epidermal keratinocytes, 
thus results suggest that IL-17A is the main regulator of both S100-proteins (Figure 3.27 and 3.28).  
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The highly homolog proteins psoriasin (S100A7) and koebnerisin (S100A15) have different 
expression patterns and distinct functions and should be discriminated (Madsen et al., 1991; Wolf et 
al., 2003). In addition to their function as AMPs, psoriasin (S100A7) and koebnerisin (S100A15) act as 
chemoattractants for leukocytes through different mechanisms (Büchau and Gallo, 2007; Gläser et 
al., 2005; Wolf et al., 2010b).  
Together, data suggest that the increased S100 production by epidermal keratinocytes in a complex 
Th17-mediated micro milieu is inhibited by vitamin D analogs. The reduced amount of infiltrating 
immune cells in psoriasis could explain the marked suppression of the psoriasin (S100A7) and 
koebnerisin (S100A15) expression in psoriatic plaques after calcipotriol treatment (Hegyi et al., 2012; 
Ikeda et al., 2010; van der Vleuten et al., 1996). Thus, vitamin D analogs are able to interfere with 
the inflammatory feedback loop in psoriatic skin by suppressing the Th17-induced pro-inflammatory 
functions of psoriasin (S100A7) and koebnerisin (S100A15) as chemoattractants and ‘alarmins’(Hegyi 
et al., 2012). 
4.4.2 Vitamin D treatment suppresses S100-protein expression by human epidermal keratinocytes 
Vitamin D analogs are established for topical treatment of psoriasis, but until now the mechanism 
responsible for the anti-psoriatic effect is not fully understood (Fogh and Kragballe, 1997). 
Differently than reported before a decreased expression of psoriasin (S100A7) and koebnerisin 
(S100A15) could be observed after calcipotriol-treated psoriatic skin (Peric et al., 2009) in vivo, also 
in vitro a Th17 induced down-regulated S100 RNA-level was measured after vitamin 1.25D3 
treatment of combined IL-17A and TNFα or IL-22 stimulated keratinocytes (Figure 3.29 and 3.30). 
However, this study demonstrated that calcipotriol is responsible for a decreased expression of 
psoriasin (S100A7) and koebnerisin (S100A15) in psoriatic lesions (Figure 3.31).  
Binding of calcipotriol to the vitamin D receptor different target genes that influence the cell 
differentiation are induced (Nagpal et al., 2005; White, 2004). Furthermore, the vitamin D analog 
blocks the NF-κB activation and thus might influence the IL-17AR expression, but psoriasin (S100A7) 
and koebnerisin (S100A15) are regulated by NF-κB (Riis et al., 2004; Sinha et al., 2008) and a direct 
effect of the S100 expression by blocking the IL-17A receptor is possible. In a psoriatic Th1/Th17 
milieu, vitamin 1.25D3 treated epidermal keratinocytes the expression of psoriasin (S100A7) and 
koebnerisin (S100A15) is reduced.  
The multifunctional S100-proteins are reduced and thereby their multifunctional capacity. Because 
the amount of infiltrating leukocytes is reduced, also the expressed cytokines are less, which in turn 
induce the expression of both S100-proteins. This study allowed a closer look of the anti-
inflammatory effect of vitamin D and its analog on the expression and regulation of the 
multifunctional psoriasin (S100A7) and koebnerisin (S100A15) acting as chemoattractants and 
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‘alarmins’ in psoriasis. A previous report describes that IL-17 down-regulates the expression of 
filaggrin, important for epidermal maturation, and additionally the pro-filaggrin processing enzymes 
in human epidermal keratinocytes (Gutowska-Owsiak et al., 2012), indicating a further effect of 
calcipotriol treatment. 
Taken together, this study shows that IL-17A combined with TNFα were the main inducers of 
psoriasin (S100A7) and koebnerisin (S100A15) in human epidermal keratinocytes in vitro. Also T cell 
supernatants of patients with psoriasis increased the expression of both S100-proteins, with a closer 
look IL-17A was identified as the responsible cytokine for the up-regulated expression. Furthermore, 
it was shown that vitamin D decreased the IL-17A induced S100-expression in human epidermal 
keratinocytes. Additionally, a decreased expression of psoriasin (S100A7) and koebnerisin (S100A15) 
could be measured in patients with calcipotriol treated psoriasis. 
 
This study identified non-infectious intrinsic molecular patterns that regulate NALP1 inflammasome 
activity in Th17-mediated autoimmune psoriasis that could lead to novel therapeutic approaches 
that target these patterns. The observed IL-17A-mediated psoriasin (S100A7) expression and the 
psoriasin (S100A7)-regulated NALP1 inflammasome activity in keratinocytes suggest a pathogenetic 
link to Th17-mediated diseases. Topical vitamin analogs strongly suppress psoriasin (S100A7) 
expression in lesional psoriasis while ameliorating the cutaneous inflammation. Furthermore, anti-IL-
17A blocks psoriasin (S100A7) expression in epidermal keratinocytes and the success of Th17 
interfering therapies in NALP1 associated diseases, such as psoriasis supports this hypothesis 
(McGovern et al., 2012; Salskov-Iversen et al., 2011; Zwicker et al., 2012). Besides in psoriasis, the 
damage associated patterns cytosolic DNA and psoriasin (S100A7) are also present in other 
autoimmune diseases of the skin and might trigger the NALP1 inflammasome activation, such as in 
systemic lupus erythematosus (Kreuter et al., 2011; Sun et al., 2000). These results further showed 
that the epidermal IL-1β release is dependent on the surrounding cytokine-milieu, which controls 
inflammasome activity in the skin and supports the relevance of the NALP1 inflammasome. Thus, the 
observations may provide another molecular mechanism for the mode of action of current therapies 
in psoriasis and other Th17-mediated auto-inflammatory diseases. 
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Summary 
 
In skin homeostasis, psoriasin (S100A7) and koebnerisin (S100A15) are expressed in epidermal 
keratinocytes, whereas koebnerisin (S100A15) can be also detected in DCs of the dermis. In this 
thesis, both S100-proteins could be detected in monocytes, leukocytes, neutrophils and koebnerisin 
(S100A15) additionally in dermal fibroblasts. Thereby, underlining their importance for skin and 
systemic inflammation and confirming the working hypothesis of aim 1 ‘psoriasin (S100A7) and 
koebnerisin (S100A15) are further expressed by non-epithelial cells’.  
In psoriasis, a Th1/Th17-mediated autoinflammatory skin disease, psoriasin (S100A7) and 
koebnerisin (S100A15) are strongly increased in the epidermis. Cell culture experiments showed that 
Th1/Th17 cytokines induce psoriasin (S100A7) and koebnerisin (S100A15) synergistically. Beside 
endogenous cytokines, also the exogenous factor UVB was able to induce the expression of both 
S100-proteins in human epidermal keratinocytes. Thus the working hypothesis of aim 2 ‘endogenous 
and exogenous factors regulate psoriasin (S100A7) and koebnerisin (S100A15) in the skin’ could be 
confirmed.  
In addition to psoriasin (S100A7) and koebnerisin (S100A15), also the NALP1 inflammasome 
components were increased in the plaques of psoriatic patients. In particular, the expression and 
localization of NALP1-specific caspase-5 could be described. In healthy skin, caspase-5 was expressed 
in the basal layer of the epidermis, whereas in psoriasis expression extended in the whole epidermis. 
The Th1/Th17 cytokines IFNγ and IL-17A induced the NALP1 inflammasome components 
synergistically, similar to S100-proteins. In the same settings other inflammasome complexes, such 
as NALP3 and AIM2, were down-regulated. In this thesis, two new functions of the multifunctional 
psoriasin (S100A7) and koebnerisin (S100A15) could be described. First, psoriasin (S100A7) induced 
the IL-1β release in epidermal keratinocytes through regulation of the NALP1 inflammasome in a 
defined Th1/Th17 cytokine-milieu. Furthermore, psoriasin (S100A7) and koebnerisin (S100A15) 
acted as ‘alarmins’, together, they induced the expression of pro-inflammatory cytokines, confirming 
the working hypothesis of aim 3 ‘psoriasin (S100A7) and koebnerisin (S100A15) act as pro-
inflammatory ‘alarmins’ and as novel regulators for inflammasome activity and IL-1β release in 
human skin’.  
To receive mature IL-1β, priming and activation of inflammasomes are required. Psoriasin (S100A7), 
but not koebnerisin (S100A15), was able to prime the inflammasome, illustrating their functionally 
differences. This thesis could show that also the NALP1 inflammasome got activated by cytosolic 
dsDNA. Furthermore, IL-17A seemed to have a suppressive effect on the IL-1β release after priming 
and activating the inflammasome complex in epidermal keratinocytes.  
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T cell supernatants of patients with psoriasis increased the expression of psoriasin (S100A7) and 
koebnerisin (S100A15) IL-17A-dependent in keratinocytes. Addition of vitamin D suppressed the IL-
17A induced expression of both S100-proteins in cultured epidermal keratinocytes. Accordingly, 
vitamin D analog calcipotriol decreased the expression of psoriasin (S100A7) and koebnerisin 
(S100A15) in plaques of psoriatic patients. Thus, the working hypothesis of aim 4 ‘vitamin D acts 
anti-inflammatory by down-regulating psoriasin (S100A7) and koebnerisin (S100A15) in chronic 
inflamed skin’ could be confirmed in this thesis. 
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Zusammenfassung 
 
In der gesunden Haut werden Psoriasin (S100A7) und Koebnerisin (S100A15) hauptsächlich in 
epidermalen Strukturen exprimiert. In dieser Arbeit konnte gezeigt werden, dass beide S100-
Proteine zudem in Monozyten, Leukozyten und Neutrophilen gebildet werden. Zusätzlich wurde 
Koebnerisin (S100A15) in dermalen Fibroblasten detektiert. Durch das umfangreichere 
Expressionsspektrum wird ihre Bedeutung für die Haut und systemische Entzündung erweitert und 
die Arbeitshypothese der ersten Zielsetzung ‚Psoriasin (S100A7) und Koebnerisin (S100A15) werden 
auch in nicht-epithelialen Zellen exprimiert‘ bestätigt. 
In der Psoriasis, eine Th1/Th17 mediierte autoinflammatorische Hauterkrankung, sind Psoriasin 
(S100A7) und Koebnerisin (S100A15) in der Epidermis stark überexprimiert. Zellkulturversuche 
zeigten, dass Th1/Th17 Zytokine Psoriasin (S100A7) und Koebnerisin (S100A15) synergistisch 
induzieren. Neben endogenen Zytokinen induzierte der exogene Faktor UVB die Expression beider 
S100-Proteine in humanen epidermalen Keratinozyten. Die Arbeitshypothese der zweiten 
Zielsetzung ‚endogene und exogene Faktoren regulieren Psoriasin (S100A7) und Koebnerisin 
(S100A15) in der Haut‘ konnte somit bestätigt werden. 
Zusätzlich zu Psoriasin (S100A7) und Koebnerisin (S100A15) wurde auch eine erhöhte Expression des 
NALP1 Inflammasomes in Haut-Plaques von Psoriasispatienten nachgewiesen. In gesunder Haut 
wurde Caspase-5 in der epidermalen Basalschicht detektiert, in psoriatischer Haut hingegen, breitete 
sich die Expression auf die gesamte Epidermis aus. Die Th1/Th17 Zytokine IFNγ und IL-17A 
induzierten Komponenten des NALP1 Inflammasomes synergistisch, vergleichbar mit dem Effekt auf 
die S100-Proteine. Im gleichen Versuchsansatz konnte eine reduzierte Expression von anderen 
Inflammasomen, z.B. NALP3 und AIM2, nachgewiesen werden. Diese Arbeit beschreibt zwei neue 
Funktionen der multifunktionellen Proteine Psoriasin (S100A7) und Koebnerisin (S100A15). Zum 
einen induzierte Psoriasin (S100A7) in epidermalen Keratinozyten eine IL-1β Freisetzung durch die 
Regulation des NALP1 inflammasomes in einem spezifischen Th1/Th17 Zytokinmilieu. Zum anderen 
konnte gezeigt werden, dass Psoriasin (S100A7) und Koebnerisin (S100A15) als ‚Alarmine‘ wirken, 
indem sie gemeinsam die Expression von pro-inflammatorischen Zytokinen induzieren, wodurch die 
Arbeitshypothese der dritten Zielsetzung ‚Psoriasin (S100A7) und Koebnerisin (S100A15) wirken als 
pro-inflammatorische ‚Alarmine‘ und als neue Regulatoren der Inflammasome Aktivität und 
bedingen dadurch eine IL-1β Freisetzung in humaner Haut‘ bestätigt wurde. 
Um freies IL-1β zu erhalten, muss das Inflammasome ‚vorstimuliert‘ und aktiviert werden. Psoriasin 
(S100A7), jedoch nicht Koebnerisin (S100A15), konnte das Inflammasome ‚vorzustimulieren‘, was 
ihre funktionellen Unterschiede zeigt. Weiterhin konnte in dieser Arbeit gezeigt werden, dass das 
Zusammenfassung 
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NALP1 Inflammasome durch zytosolische doppelsträngige DNS aktiviert wird. Für IL-17A wurde 
außerdem ein suppressiver Einfluss auf die Vorstimulation und Aktivierung des Inflammasoms in 
epidermalen Keratinozyten nachgewiesen. 
T-Zellüberstände von Psoriasispatienten induzierten IL-17A abhängig die Expression von Psoriasin 
(S100A7) und Koebnerisin (S100A15) in Keratinozyten. Die Zugabe von Vitamin D unterdrückte die 
IL-17A abhängige Expression beider S100-Proteine in Zellkulturversuchen. Dementsprechend konnte 
gezeigt werden, dass in Haut-Plaques von Psoriasispatienten nach Behandlung mit dem Vitamin D 
Analog Calcipotriol die Expression von Psoriasin (S100A17) und Koebnerisin (S100A15) reduziert 
wird. Die Arbeitshypothese der vierten Zielsetzung ‚Vitamin D wirkt anti-inflammatorisch durch die 
Runterregulation von Psoriasin (S100A7) und Koebnerisin (S100A15) in chronisch entzündeter Haut‘ 
konnte somit bestätigt werden. 
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